0000105770-26-000121 | 10-Q | XBRL Viewer | West Pharmaceutical Services INC

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 28, 2025	May 31, 2025	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)		2,000,000.0
Shares available for issuance under the 2016 Plan (in shares)			2,700,000		2,700,000
Stock options, granted (in shares)					104,187
Stock options, weighted average exercise price (in dollars per share)					$ 285.51
Stock options, weighted average grant date fair value (in dollars per share)					$ 123.37
Risk-free interest rate (in hundredths)					4.10%
Expected life (in years)					6 years 10 months 24 days
Stock volatility (as a percent)					35.10%
Dividend yield (as a percent)					0.30%
Stock-based compensation expense			$ 4.3	$ 8.4	$ 21.8	$ 17.1
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Rate shares are reduced for each award granted (in shares)		1
Award Types Other than Stock Options and Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Rate shares are reduced for each award granted (in shares)	2.5	2.0
Performance Share Unit (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)					81,450
Grant date fair value (in dollars per share)					$ 278.08
Performance Share Unit (PSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target award percentage					0.00%
Performance Share Unit (PSUs) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target award percentage					200.00%
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)					54,154
Grant date fair value (in dollars per share)					$ 279.63

Debt

9 Months Ended

Sep. 30, 2026

Debt Disclosure [Abstract]

Debt

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2026.


($ in millions)	September 30, 2026		December 31, 2025
Term Loan, due July 2, 2027 (5.25%)	$	130.0	$	130.0
Series C notes, due July 5, 2027 (4.02%)	73.0		73.0
	203.0		203.0
Less: unamortized debt issuance costs for Term Loan and Series Notes	0.1		0.2
Total debt	202.9		202.8
Less: current portion of long-term debt	—		—
Long-term debt, net	$	202.9	$	202.8

Term Loan

At September 30, 2026, the Company had $130.0 million in borrowings under the Term Loan which were classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Multi-Currency Revolving Credit Facility

At September 30, 2026, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility, including outstanding letters of credit of $2.3 million, was $497.7 million.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2026, we were in compliance with all of our debt covenants.

In accordance with ASC 470-10-45-14 and ASC 855, the Term Loan (due July 2, 2027) and the Series C Notes (due July 5, 2027) are classified as long-term debt in the accompanying balance sheet as of September 30, 2026, as the refinancing was completed prior to the issuance of these financial statements as described below.

Subsequent Event — Debt Refinancing

Entry into New Credit Agreement

On October 26, 2026, the Company completed a refinancing of its senior unsecured credit facilities by entering into a new senior unsecured credit agreement with Bank of America, N.A., as administrative agent, swing line lender and an issuing lender, and the other lenders from time to time party thereto (as amended, restated, extended, supplemented or otherwise modified from time to time, the "New Credit Agreement").

The New Credit Agreement (i) has a maturity date of October 26, 2031 (subject to certain extension mechanics therein by which the Company may request maturity date extensions of the revolving credit facility), (ii) provides for revolving advances up to an aggregate principal amount of $750 million at any one time outstanding (subject to satisfaction of certain conditions at the time advances are made) and (iii) provides for a term loan advance on the closing date in an aggregate principal amount of $200 million (which shall have quarterly amortization payments starting in March 31, 2028 ranging from $1.25 million to $2.5 million per quarter as set forth in the New Credit Agreement with the balance due at maturity) (such term loan, the "New Term Loan A").

Revolving advances are available under the New Credit Agreement in U.S. dollars and certain optional currencies. The applicable margin used in connection with interest rates and the commitment fee is based on the Company’s net leverage ratio. The applicable margin for revolving advances that are term Secured Overnight Financing Rate loans and optional currency loans and for letter of credit fees ranges from 1.000% to 1.500%, and the applicable margin for revolving advances that are base rate loans ranges from 0.000% to 0.500%. The applicable margin for term loans that are term Secured Overnight Financing Rate loans ranges from 1.125% to 1.750%, and the applicable margin for term loans that are base rate loans ranges from 0.125% to 0.750%. The Company will also pay a commitment fee based on its net leverage ratio on the actual daily unused amount of the aggregate revolving commitments ranging from 0.125% to 0.225%.

The New Credit Agreement contains a financial covenant limiting, as of the last day of each fiscal quarter, the Company's net leverage ratio, measured for the preceding four fiscal quarters, to not more than 3.50 to 1.0 (or 4.00 to 1.0 during material acquisition periods, subject to certain limitations), all as calculated in accordance with the terms of the New Credit Agreement.

The New Term Loan A advance of $200 million refinanced and replaced the Company's existing $130.0 million Term Loan A, which was due July 2, 2027.

Unamortized debt issuance costs associated with the prior term loan were written off in connection with the extinguishment and new debt issuance costs will be capitalized and amortized over the life of the New Term Loan A.

Extinguishment of Series C Senior Notes: The Company has delivered a notice to noteholders to repay and extinguish its outstanding Series C senior notes in an outstanding principal amount of $73.0 million, with an expected repayment date to occur on or about November 2, 2026, using, among other available cash, proceeds from the New Term Loan A. The Series C senior notes bore interest at 4.02% and were originally due July 5, 2027. No prepayment make-whole premium is incurred in connection with the extinguishment.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies From time to time, we are involved in various proceedings, lawsuits, disputes and claims arising in the ordinary course of the Company’s business, whether that be matters involving commercial operations, product liability, intellectual property or employment actions, including class action lawsuits. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated based on circumstances and assumptions existing at the time. Unless otherwise disclosed below, while the outcome of such claims cannot be predicted with certainty, we believe their ultimate resolution is not expected to have a material adverse effect on our business, financial condition, results of operations or liquidity. However, if an unfavorable ruling were to occur in any specific case, a material impact on the results of operations could be possible for that period. Securities Class Action On May 5, 2025, New England Teamsters Pension Fund filed a class action against us and certain of our current and former officers in the United States District Court for the Eastern District of Pennsylvania, purportedly on behalf of a class of the Company’s investors who purchased or otherwise acquired the Company’s common stock between February 16, 2023 and February 12, 2025. On July 23, 2025, the court appointed lead plaintiffs in the action. On October 15, 2025, the lead plaintiffs filed an amended complaint. The amended complaint alleges violations of Sections 10(b), 20(a) and 20A of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder in connection with 1) various public statements made by the Company and certain current and former officers regarding its business, operations and prospects and 2) certain current and former officers' transactions in the Company's stock. The action seeks unspecified damages, costs and expenses, including attorneys’ fees. On December 18, 2025, the defendants filed their first motion to dismiss the amended complaint. Pursuant to the scheduling order entered by the court, the lead plaintiffs’ opposition to the motion to dismiss was filed on February 24, 2026, and the defendants filed their reply on March 31, 2026. We believe the claims in the amended complaint are without merit and we intend to vigorously defend against such claims. Given the nature of the case, including that the proceedings are in their early stages, we are unable at this time to reasonably estimate losses, if any, or form a judgment that an unfavorable outcome is either probable or remote. There have been no significant changes to commitments and contingencies since December 31, 2025.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Cash flows from operating activities:
Net income	$ 506.8	$ 361.6
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	136.0	122.2
Amortization	1.3	2.2
Stock-based compensation	21.8	17.1
Gain on sale of SmartDose® 3.5mL On-Body Delivery System	(55.7)	0.0
Non-cash restructuring charges	3.8	2.5
Asset impairments	4.6	4.4
Other non-cash items, net	(7.0)	(4.4)
Changes in assets and liabilities	(208.2)	(1.9)
Net cash provided by operating activities	403.4	503.7
Cash flows from investing activities:
Capital expenditures	(125.0)	(209.8)
Proceeds from sale of business	126.9	0.0
Disbursement associated with the sale of assets	(8.9)	0.0
Net cash used in investing activities	(7.0)	(209.8)
Cash flows from financing activities:
Borrowings under revolving credit agreements	50.0	0.0
Repayments under revolving credit agreements	(50.0)	0.0
Principal repayments on finance leases	(1.2)	(0.8)
Excise tax payments	(0.8)	(4.2)
Dividend payments	(47.0)	(45.4)
Proceeds from stock-based compensation awards	17.0	8.2
Employee stock purchase plan contributions	5.8	5.4
Shares purchased under share repurchase programs	(685.3)	(134.0)
Shares repurchased for employee tax withholdings	(3.8)	(2.6)
Net cash used in financing activities	(715.3)	(173.4)
Effect of exchange rates on cash	(8.3)	23.4
Net (decrease) increase in cash and cash equivalents	(327.2)	143.9
Cash, including cash equivalents at beginning of period	791.3	484.6
Cash, including cash equivalents at end of period	464.1	628.5
Supplemental cash flow information:
Accrued capital expenditures	$ 28.3	$ 38.1

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2026	Dec. 31, 2025
Fair Value Disclosures [Abstract]
Long-term debt, estimated fair value	$ 202.1	$ 202.4
Long-term debt, carrying amount	$ 202.9	$ 202.8

- Definition

Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

+ Details

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

+ Details

Inventories (Tables)

9 Months Ended

Sep. 30, 2026

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:


($ in millions)	September 30, 2026		December 31, 2025
Raw materials	$	170.1	$	163.2
Work in process	95.4		103.2
Finished goods	199.2		177.5
	$	464.7	$	443.9

Derivative Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2026

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Foreign Exchange Contracts and Foreign Exchange Rate Risk

The following table summarizes the total amount of the following forward exchange contracts as fair value hedges at the following dates:


(in millions)		September 30,		December 31,
Forward Exchange Contracts	Currency	2026		2025
Cross-Currency Intercompany Loans	SGD	SGD	209.1	SGD	421.9

Cross-Currency Intercompany Demand Notes	EUR	€	23.5	€	23.5

As of September 30, 2026, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:


(in millions)		Sell
Currency	Purchase	USD	EUR
EUR	30.3	35.8	—
JPY	4,943.4	19.1	11.2
SGD	66.2	46.1	5.9

Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings

The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:


	Amount of Gain (Loss) Recognized in Income for the				Amount of Gain (Loss) Recognized in Income for the
	Three Months Ended September 30,				Nine Months Ended September 30,				Location on Statement of Income
($ in millions)	2026		2025		2026		2025
Fair Value Hedges:
Hedged item (intercompany loan)	$	(3.3)	$	3.9	$	(8.2)	$	7.3	Other expense (income)
Derivative designated as hedging instrument	3.3		(3.9)		8.2		(7.3)		Other expense (income)
Amount excluded from effectiveness testing	0.4		(0.4)		(0.5)		(1.3)		Other expense (income)
Total	$	0.4	$	(0.4)	$	(0.5)	$	(1.3)

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:


	Amount of Gain (Loss) Recognized in OCI for the				Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the				Location of (Gain) Loss Reclassified from Accumulated OCI into Income
	Three Months Ended September 30,				Three Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Fair Value Hedges:
Foreign currency hedge contracts	$	(0.2)	$	0.2	$	—	$	—	Other expense (income)
Total	$	(0.2)	$	0.2	$	—	$	—
Cash Flow Hedges:
Foreign currency hedge contracts	$	0.8	$	0.8	$	(0.1)	$	0.3	Net sales
Foreign currency hedge contracts	0.2		(2.5)		1.1		(0.5)		Cost of goods and services sold

Forward treasury locks	—		—		0.1		0.1		Interest expense
Total	$	1.0	$	(1.7)	$	1.1	$	(0.1)
Net Investment Hedges:

Cross-currency swap	$	(3.0)	$	2.4	$	—	$	—	Other expense (income)
Total	$	(3.0)	$	2.4	$	—	$	—


	Amount of Gain (Loss) Recognized in OCI for the				Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the				Location of (Gain) Loss Reclassified from Accumulated OCI into Income
	Nine Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Fair Value Hedges:
Foreign currency hedge contracts	$	—	$	1.0	$	—	$	—	Other expense (income)
Total	$	—	$	1.0	$	—	$	—
Cash Flow Hedges:
Foreign currency hedge contracts	$	0.7	$	(1.8)	$	0.3	$	0.4	Net sales
Foreign currency hedge contracts	(2.4)		4.0		2.2		(0.3)		Cost of goods and services sold

Forward treasury locks	—		—		0.1		0.1		Interest expense
Total	$	(1.7)	$	2.2	$	2.6	$	0.2
Net Investment Hedges:

Cross-currency swap	$	(1.2)	$	(3.8)	$	—	$	—	Other expense (income)
Total	$	(1.2)	$	(3.8)	$	—	$	—

The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in the condensed consolidated statements of income:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Net sales	$	(0.1)	$	0.3	$	0.3	$	0.4
Cost of goods and services sold	$	1.1	$	(0.5)	$	2.2	$	(0.3)
Interest expense	$	0.1	$	0.1	$	0.1	$	0.1

Schedule of Derivative Instruments Not Designated as Hedges

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:


	Amount of Gain (Loss) Recognized in Income for the				Amount of Gain (Loss) Recognized in Income for the
	Three Months Ended September 30,				Nine Months Ended September 30,				Location on Statement of Income
($ in millions)	2026		2025		2026		2025
Commodity call options	$	1.9	$	(0.1)	$	2.9	$	(0.5)	Other expense (income)
Currency Forwards	0.1		0.3		1.3		1.2		Other expense (income)
Total	$	2.0	$	0.2	$	4.2	$	0.7

Net Income Per Share - Narrative (Details) - shares	3 Months Ended		9 Months Ended
Net Income Per Share - Narrative (Details) - shares	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Feb. 28, 2026	Dec. 31, 2024	Feb. 28, 2023
Earnings Per Share [Abstract]
Antidilutive options excluded from computation of diluted net income per share (in shares)	100,000	400,000	300,000	400,000
Stock repurchase program, shares authorized (in shares)					1,000,000,000.0	550,000	1,000,000,000.0

Affiliated Companies- Schedule of Amounts Due to Affiliates in the Condensed Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Sep. 30, 2026	Dec. 31, 2025
Schedule of Equity Method Investments [Line Items]
Payables due to affiliates	$ 156.3	$ 175.3
Receivables due from affiliates	139.5	168.6
Affiliated Entity
Schedule of Equity Method Investments [Line Items]
Payables due to affiliates	34.2	26.2
Receivables due from affiliates	$ 3.6	$ 2.0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

+ Details

Fair Value Measurements

9 Months Ended

Sep. 30, 2026

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.

•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:


	Balance at		Basis of Fair Value Measurements
($ in millions)	September 30, 2026		Level 1		Level 2		Level 3
Assets:
Deferred compensation assets	$	9.9	$	9.9	$	—	$	—
Money market funds	144.2		144.2		—		—
Time deposits	53.7		—		53.7		—
Foreign currency contracts	7.3		—		7.3		—
Cross-currency swap	23.2		—		23.2		—
Commodity call options	3.1		—		3.1		—
	$	241.4	$	154.1	$	87.3	$	—
Liabilities:
Contingent consideration	$	0.9	$	—	$	—	$	0.9
Deferred compensation liabilities	10.0		10.0		—		—
Foreign currency contracts	3.1		—		3.1		—
	$	14.0	$	10.0	$	3.1	$	0.9


	Balance at		Basis of Fair Value Measurements
($ in millions)	December 31, 2025		Level 1		Level 2		Level 3
Assets:
Deferred compensation assets	$	10.0	$	10.0	$	—	$	—
Money market funds	443.9		443.9		—		—
Time deposits	41.6		—		41.6		—
Foreign currency contracts	0.2		—		0.2		—
Cross-currency swap	24.7		—		24.7		—
Commodity call options	0.3		—		0.3		—
	$	520.7	$	453.9	$	66.8	$	—
Liabilities:
Contingent consideration	$	2.2	$	—	$	—	$	2.2
Deferred compensation liabilities	10.1		10.1		—		—
Foreign currency contracts	7.6		—		7.6		—
	$	19.9	$	10.1	$	7.6	$	2.2

Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. Money market funds are included within cash and cash equivalents and are valued based on quoted market prices in active markets, with no valuation adjustment. Time deposits are included within cash and cash equivalents and are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities.

Other Financial Instruments

We believe that the carrying amounts of our cash and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2026, the estimated fair value of long-term debt was $202.1 million compared to a carrying amount of $202.9 million. At December 31, 2025, the estimated fair value of the Company's debt was $202.4 million and the carrying amount was $202.8 million. As of September 30, 2026 and December 31, 2025 all debt is classified as long-term.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Affiliated Companies - Schedule of Aggregate Carrying Amount (Details) - USD ($) $ in Millions	Sep. 30, 2026	Dec. 31, 2025
Schedule of Equity Method Investments [Line Items]
Total investments in affiliated companies	$ 215.8	$ 212.3
Affiliated Entity
Schedule of Equity Method Investments [Line Items]
Equity method affiliates	215.2	208.3
Non-equity method affiliates	$ 0.6	$ 4.0

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References + Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Segment Information

9 Months Ended

Sep. 30, 2026

Segment Reporting [Abstract]

Segment Information

Our business operations are organized into two reportable segments, Proprietary Products and West Vantage. Effective in the first quarter of 2026, the Company renamed its "Contract-Manufactured Products" reportable segment to "West Vantage™" to better align with its current strategic focus and offerings. This change in name does not affect the composition of the reportable segment, nor does it impact previously reported segment financial information. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our West Vantage reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

The Chief Operating Decision Maker ("CODM") is the Chief Executive Officer. The CODM evaluates the performance of our segments based upon, among other things, segment net sales and segment operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position. The CODM considers budget-to-actual variances and variances against prior years within segment operating profit when making decisions about allocating resources to the segments.

The following table presents information about our reportable segments, reconciled to consolidated totals:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Net sales:
Proprietary Products	$	728.8	$	647.5	$	2,145.7	$	1,830.3
West Vantage	145.7		157.1		446.0		438.8

Consolidated net sales	$	874.5	$	804.6	$	2,591.7	$	2,269.1

The following tables provide summarized financial information for our two reportable segments and corporate and unallocated:


($ in millions)	September 30, 2026		December 31, 2025
Assets
Proprietary Products	$	2,925.2	$	2,987.0
West Vantage	696.8		718.1
Corporate and Unallocated (1)	438.7		564.9
Total consolidated	$	4,060.7	$	4,270.0

(1) Corporate and unallocated assets primarily include investments in affiliated companies, cash and cash equivalents, property, plant and equipment used in our corporate operations and deferred income taxes.


($ in millions)	Three Months Ended September 30,				Nine Months Ended September 30,
Depreciation and Amortization	2026		2025		2026		2025
Proprietary Products	$	37.6	$	35.1	$	110.3	$	101.5
West Vantage	7.5		7.1		24.7		20.3
Corporate and Unallocated	0.8		0.8		2.3		2.6
Total consolidated	$	45.9	$	43.0	$	137.3	$	124.4


($ in millions)	Three Months Ended September 30,				Nine Months Ended September 30,
Capital Expenditures	2026		2025		2026		2025
Proprietary Products	$	28.6	$	47.7	$	100.5	$	148.1
West Vantage	8.2		13.6		18.9		57.2
Corporate and Unallocated	2.3		2.0		5.6		4.5
Total consolidated	$	39.1	$	63.3	$	125.0	$	209.8

The following table provides summarized financial information for our segments:


	Three months ended September 30, 2026						Three months ended September 30, 2025
($ in millions)	Proprietary Products		West Vantage		Total		Proprietary Products		West Vantage		Total
Net sales	$	728.8	$	145.7	$	874.5	$	647.5	$	157.1	$	804.6
Cost of goods and services sold	405.4		121.7				383.5		126.8
Research and development	18.3		—				17.1		—
Selling, general and administrative expenses	74.5		8.1				65.6		7.5
Other segment expense (income)(1)	—		0.4				6.1		0.5
Segment operating profit	$	230.6	$	15.5	$	246.1	$	175.2	$	22.3	$	197.5
Reconciliation of profit or loss:
Stock-based compensation					(4.3)						(8.4)
Corporate general costs(2)					(20.3)						(19.0)
Unallocated items:
Restructuring and other charges(3)					(6.3)						(2.5)

M&A activities, including SmartDose® 3.5mL sale(4)					54.0						—



Other(7)					(1.8)						—
Total consolidated operating profit					267.4						167.6
Interest (income) expense and other nonoperating expense (income), net					(0.3)						(4.3)
Income before income taxes and equity in net income of affiliated companies					$	267.7					$	171.9


	Nine Months ended September 30, 2026						Nine months ended September 30, 2025
($ in millions)	Proprietary Products		West Vantage		Total		Proprietary Products		West Vantage		Total
Net sales	$	2,145.7	$	446.0	$	2,591.7	$	1,830.3	$	438.8	$	2,269.1
Cost of goods and services sold	1,241.2		377.5				1,107.8		361.2
Research and development	53.8		—				52.5		—
Selling, general and administrative expenses	209.0		24.2				187.4		22.1
Other segment expense (income)(1)	10.0		0.3				15.1		1.9
Segment operating profit	$	631.7	$	44.0	$	675.7	$	467.5	$	53.6	$	521.1
Reconciliation of profit or loss:
Stock-based compensation					(21.8)						(17.1)
Corporate general costs(2)					(54.0)						(53.6)
Unallocated items:
Restructuring and other charges(3)					(9.3)						(21.9)

M&A activities, including SmartDose® 3.5mL sale(4)					45.7						—
Cost-method investment activity(5)					(3.5)						—

Amortization of acquisition-related intangible assets(6)					—						(0.2)
Other(7)					(9.2)						—

Total consolidated operating profit					623.6						428.3
Interest (income) expense and other nonoperating expense (income), net					(4.3)						(11.1)
Income before income taxes and equity in net income of affiliated companies					$	627.9					$	439.4

(1) Other segment expense (income) primarily includes foreign exchange transaction gains and losses, adjustments to contingent consideration and (gain) loss on oil hedges attributable to the segments during the three and nine months ended September 30, 2026 and 2025.

(2) Corporate general costs include executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(3) During the three and nine months ended September 30, 2026, the Company recorded pre-tax charges of $6.3 million and $9.3 million, respectively, related to our two existing restructuring programs: (i) $5.8 million and $7.7 million, respectively, within other expense (income), related to severance and retention benefit charges and the acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million and $1.6 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. During the three and nine months ended September 30, 2025, the Company recorded pre-tax charges of $2.5 million and $21.9 million, respectively, related to our two existing restructuring programs: (i) $0.9 million and $17.5 million, respectively, within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $1.6 million and $4.4 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries.

(4) During the three and nine months ended September 30, 2026, the Company recorded a pre-tax benefit of $54.0 million and $45.7 million, respectively, related to M&A activities, including the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The net benefit is composed of a net gain on the sale of its SmartDose® 3.5mL On-Body Delivery System assets of $55.7 million for the three and nine months ended September 30, 2026 within other expense (income). The Company recorded a net benefit of $1.9 million and net charges of $0.3 million, respectively, within other expense (income), related to employee benefit costs in connection with the sale agreement. The Company recorded the remaining $3.6 million and $9.7 million, respectively, within selling, general and administrative expenses, relating to professional services in connection with the sale agreement and other M&A activities.

(5) During the nine months ended September 30, 2026, the Company recorded cost-method investment impairment charges of $3.5 million within other expense (income).

(6) During the three and nine months ended September 30, 2025, we recorded $0.0 million and $0.2 million, respectively, of amortization expense within selling, general and administrative expenses associated with an intangible asset acquired during the second quarter of 2020.

(7) Other includes nonrecurring professional fees associated with various items including certain legal matters and our cybersecurity incident from May 2026. These charges are recorded within selling, general and administrative expenses.

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details

Basis of Presentation (Policies)	9 Months Ended
Basis of Presentation (Policies)	Sep. 30, 2026
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2026, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Annual Report”). The results of operations for any interim period are not necessarily indicative of the results for the full year.
Recently Adopted Standards and Standards Issued Not Yet Adopted	Recently Adopted Standards In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-09, Income Taxes: Improvements to Income Tax Disclosures, that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. The Company adopted and implemented the applicable disclosure requirements within its 2025 Form 10-K filed on February 17, 2026 on a prospective basis. Standards Issued Not Yet Adopted In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, that seeks to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity: (1) disclose the amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each of the Company's relevant expense captions; (2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. This guidance is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of this guidance on our financial statements and disclosures.
Revenue	Revenue Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels: •Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. •Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. •Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-17

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-19

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (e)
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Leases - Schedule of Lessee, Operating and Finance Lease, Liability, Maturity (Details) $ in Millions	Sep. 30, 2026 USD ($)
Operating Leases
2026 (remaining period as of September 30, 2026)	$ 6.9
2027	23.1
2028	21.0
2029	15.5
2030	8.3
Thereafter	51.6
Operating leases liabilities payments due	126.4
Less: imputed lease interest	(24.3)
Total lease liabilities	102.1
Finance Leases
2026 (remaining period as of September 30, 2026)	0.4
2027	1.5
2028	1.3
2029	0.8
2030	5.7
Thereafter	0.5
Finance leases liabilities payments due	10.2
Less: imputed lease interest	(1.3)
Total lease liabilities	$ 8.9

Affiliated Companies - Narrative (Details) $ in Millions		3 Months Ended		9 Months Ended
Affiliated Companies - Narrative (Details) $ in Millions	Jul. 14, 2026 agreement	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)
Schedule of Equity Method Investments [Line Items]
Cost-method investment impairment charges		$ 0.0	$ 0.0	$ 3.5	$ 0.0
Daikyo Seiko, Ltd. ("Daikyo")
Schedule of Equity Method Investments [Line Items]
Ownership interest	49.00%
Number of new Distributorship Agreements \| agreement	2
Distributorship agreement, term	10 years
Corporate And Reconciling Items
Schedule of Equity Method Investments [Line Items]
Cost-method investment impairment charges				3.5	$ 0.0
Corporate And Reconciling Items \| Affiliated Entity
Schedule of Equity Method Investments [Line Items]
Cost-method investment impairment charges				$ 3.5

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Leases (Tables)

9 Months Ended

Sep. 30, 2026

Leases [Abstract]

Schedule of Lease Cost and Lease Cash Flow and Supplemental Information and Lease Terms and Discount Rates

The components of lease expense were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Operating lease cost	$	8.0	$	6.9	$	22.5	$	20.3
Finance lease - amortization of right-of-use (ROU) assets	0.4		0.5		1.4		1.2
Finance lease - interest on lease liabilities	0.1		—		0.2		0.1
Short-term lease cost	1.2		1.0		3.2		2.5
Variable lease cost	2.3		2.9		7.8		8.3
Total lease cost	$	12.0	$	11.3	$	35.1	$	32.4

Supplemental cash flow information related to leases was as follows:


	Nine Months Ended September 30,
($ in millions)		2026		2025
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		$	21.3	$	19.6
Operating cash flows from finance leases		$	0.2	$	0.1
Financing cash flows from finance leases		$	1.2	$	0.8
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases		$	4.3	$	9.9
Finance leases		$	5.2	$	2.9

The following table shows the weighted average remaining lease terms and discount rates for our operating and finance leases as of the periods ended:


	September 30, 2026		December 31, 2025
Weighted average remaining lease term (in years):
Operating leases	8.2		8.3
Finance leases	3.9		4.4
Weighted average discount rate:
Operating leases	4.82	%	4.67	%
Finance leases	4.76	%	4.15	%

Schedule of Assets and Liabilities, Lessee

The following table summarizes the finance lease amounts in the condensed consolidated balance sheets:



		September 30,		December 31,
($ in millions)	Balance Sheet Classification	2026		2025

ROU assets, net	Other noncurrent assets	$	37.5	$	34.7
Lease liabilities (current)	Other current liabilities	$	1.4	$	1.5
Lease liabilities (noncurrent)	Other long-term liabilities	$	7.5	$	3.6

Schedule of Lessee, Operating Lease, Liability, Maturity

Maturities of the Company's lease liabilities as of September 30, 2026 were as follows:


($ in millions)
Year	Operating Leases		Finance Leases
2026 (remaining period as of September 30, 2026)	$	6.9	$	0.4
2027	23.1		1.5
2028	21.0		1.3
2029	15.5		0.8
2030	8.3		5.7
Thereafter	51.6		0.5
	126.4		10.2
Less: imputed lease interest	(24.3)		(1.3)
Total lease liabilities	$	102.1	$	8.9

Schedule of Lessee, Finance Lease, Liability, Maturity

Maturities of the Company's lease liabilities as of September 30, 2026 were as follows:


($ in millions)
Year	Operating Leases		Finance Leases
2026 (remaining period as of September 30, 2026)	$	6.9	$	0.4
2027	23.1		1.5
2028	21.0		1.3
2029	15.5		0.8
2030	8.3		5.7
Thereafter	51.6		0.5
	126.4		10.2
Less: imputed lease interest	(24.3)		(1.3)
Total lease liabilities	$	102.1	$	8.9

Other Expense (Income) - Narrative (Details) - USD ($) $ in Millions	1 Months Ended
	Dec. 31, 2025	Jan. 31, 2025	Sep. 30, 2026
Restructuring Cost and Reserve [Line Items]
Incremental charges			$ 20
Restructuring and related cost, cost incurred to date			$ 26
Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring and related activities, period of implementation	12 months	24 months
Restructuring and related cost	$ 12	$ 48
Effect on future earnings, amount	$ 15	$ 35
Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring and related activities, period of implementation	15 months	36 months
Restructuring and related cost	$ 16	$ 50
Effect on future earnings, amount	$ 20	$ 40

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Net Income Per Share - Schedule of Reconciliation of Basic to Diluted Net Income Per Share (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
Earnings Per Share [Abstract]
Net income	$ 214.0	$ 154.0	$ 138.8	$ 140.0	$ 131.8	$ 89.8	$ 506.8	$ 361.6
Weighted average common shares outstanding (in shares)	70.4			72.2			71.1	72.3
Dilutive effect of equity awards, based on the treasury stock method (in shares)	0.4			0.4			0.4	0.4
Weighted average shares assuming dilution (in shares)	70.8			72.6			71.5	72.7

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Millions	Sep. 30, 2026	Dec. 31, 2025
Assets:
Deferred compensation assets	$ 9.9	$ 10.0
Foreign currency contracts	7.3	0.2
Assets at fair value	241.4	520.7
Liabilities:
Contingent consideration	0.9	2.2
Deferred compensation liabilities	10.0	10.1
Foreign currency contracts	3.1	7.6
Liabilities at fair value	14.0	19.9
Cross-currency swap
Assets:
Derivative asset	23.2	24.7
Commodity call options
Assets:
Derivative asset	3.1	0.3
Money market funds
Assets:
Cash and cash equivalents	144.2	443.9
Time deposits
Assets:
Cash and cash equivalents	53.7	41.6
Level 1
Assets:
Deferred compensation assets	9.9	10.0
Foreign currency contracts	0.0	0.0
Assets at fair value	154.1	453.9
Liabilities:
Contingent consideration	0.0	0.0
Deferred compensation liabilities	10.0	10.1
Foreign currency contracts	0.0	0.0
Liabilities at fair value	10.0	10.1
Level 1 \| Cross-currency swap
Assets:
Derivative asset	0.0	0.0
Level 1 \| Commodity call options
Assets:
Derivative asset	0.0	0.0
Level 1 \| Money market funds
Assets:
Cash and cash equivalents	144.2	443.9
Level 1 \| Time deposits
Assets:
Cash and cash equivalents	0.0	0.0
Level 2
Assets:
Deferred compensation assets	0.0	0.0
Foreign currency contracts	7.3	0.2
Assets at fair value	87.3	66.8
Liabilities:
Contingent consideration	0.0	0.0
Deferred compensation liabilities	0.0	0.0
Foreign currency contracts	3.1	7.6
Liabilities at fair value	3.1	7.6
Level 2 \| Cross-currency swap
Assets:
Derivative asset	23.2	24.7
Level 2 \| Commodity call options
Assets:
Derivative asset	3.1	0.3
Level 2 \| Money market funds
Assets:
Cash and cash equivalents	0.0	0.0
Level 2 \| Time deposits
Assets:
Cash and cash equivalents	53.7	41.6
Level 3
Assets:
Deferred compensation assets	0.0	0.0
Foreign currency contracts	0.0	0.0
Assets at fair value	0.0	0.0
Liabilities:
Contingent consideration	0.9	2.2
Deferred compensation liabilities	0.0	0.0
Foreign currency contracts	0.0	0.0
Liabilities at fair value	0.9	2.2
Level 3 \| Cross-currency swap
Assets:
Derivative asset	0.0	0.0
Level 3 \| Commodity call options
Assets:
Derivative asset	0.0	0.0
Level 3 \| Money market funds
Assets:
Cash and cash equivalents	0.0	0.0
Level 3 \| Time deposits
Assets:
Cash and cash equivalents	$ 0.0	$ 0.0

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2026

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value

The following tables present the assets and liabilities recorded at fair value on a recurring basis:


	Balance at		Basis of Fair Value Measurements
($ in millions)	September 30, 2026		Level 1		Level 2		Level 3
Assets:
Deferred compensation assets	$	9.9	$	9.9	$	—	$	—
Money market funds	144.2		144.2		—		—
Time deposits	53.7		—		53.7		—
Foreign currency contracts	7.3		—		7.3		—
Cross-currency swap	23.2		—		23.2		—
Commodity call options	3.1		—		3.1		—
	$	241.4	$	154.1	$	87.3	$	—
Liabilities:
Contingent consideration	$	0.9	$	—	$	—	$	0.9
Deferred compensation liabilities	10.0		10.0		—		—
Foreign currency contracts	3.1		—		3.1		—
	$	14.0	$	10.0	$	3.1	$	0.9


	Balance at		Basis of Fair Value Measurements
($ in millions)	December 31, 2025		Level 1		Level 2		Level 3
Assets:
Deferred compensation assets	$	10.0	$	10.0	$	—	$	—
Money market funds	443.9		443.9		—		—
Time deposits	41.6		—		41.6		—
Foreign currency contracts	0.2		—		0.2		—
Cross-currency swap	24.7		—		24.7		—
Commodity call options	0.3		—		0.3		—
	$	520.7	$	453.9	$	66.8	$	—
Liabilities:
Contingent consideration	$	2.2	$	—	$	—	$	2.2
Deferred compensation liabilities	10.1		10.1		—		—
Foreign currency contracts	7.6		—		7.6		—
	$	19.9	$	10.1	$	7.6	$	2.2

Basis of Presentation (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
Basis of Presentation (Details) - USD ($) $ in Millions	Jul. 01, 2026	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2025
Intangible Asset, Finite-Lived [Line Items]
Proceeds from sale of business				$ 126.9	$ 0.0
Pre-tax gain on the sale of assets		$ 55.7	$ 0.0	55.7	$ 0.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| SmartDose® 3.5mL On-Body Delivery System And Associated Facilities
Intangible Asset, Finite-Lived [Line Items]
Proceeds from sale of business	$ 126.9
Pre-tax gain on the sale of assets	$ 55.7	$ 55.7		$ 55.7
Disposal Group, Held-for-Sale, Not Discontinued Operations \| SmartDose® 3.5mL On-Body Delivery System And Associated Facilities
Intangible Asset, Finite-Lived [Line Items]
Inventories						$ 20.5
Property, plant and equipment, net						39.1
Operating lease right-of-use assets						1.2
Goodwill						$ 0.6

New Accounting Standards	9 Months Ended
New Accounting Standards	Sep. 30, 2026
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Standards	New Accounting Standards Recently Adopted Standards In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-09, Income Taxes: Improvements to Income Tax Disclosures, that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. The Company adopted and implemented the applicable disclosure requirements within its 2025 Form 10-K filed on February 17, 2026 on a prospective basis. Standards Issued Not Yet Adopted In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, that seeks to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity: (1) disclose the amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each of the Company's relevant expense captions; (2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. This guidance is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of this guidance on our financial statements and disclosures.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480339/815-10-65-8

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480339/815-10-65-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479279/805-10-65-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-7

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org/250/tableOfContent

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

+ Details

Revenue - Schedule of Change in Contract with Customer, Asset and Liability (Details) $ in Millions	9 Months Ended
	Sep. 30, 2026 USD ($)
Contract With Customer, Asset [Roll Forward]
Contract assets, December 31, 2025	$ 11.9
Contract assets, September 30, 2026	15.1
Change in contract assets - increase (decrease)	3.2
Contract With Customer, Liability [Roll Forward]
Deferred income, December 31, 2025	(53.7)
Deferred income, September 30, 2026	(43.7)
Change in deferred income - decrease (increase)	$ 10.0

Shareholders’ Equity

9 Months Ended

Sep. 30, 2026

Equity [Abstract]

Shareholders' Equity

Shareholders’ Equity

The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2026:


	Common Shares Issued	Common Stock		Capital in Excess of Par Value		Number of Treasury Shares	Treasury Stock		Retained earnings		Accumulated other comprehensive loss		Total
(in millions)
Balance, December 31, 2025	75.3	$	18.8	$	—	3.3	$	(1,112.2)	$	4,374.9	$	(105.5)	$	3,176.0
Net income	—	—		—		—	—		138.8		—		138.8

Activity related to stock-based compensation	—	—		—		(0.1)	30.7		(21.9)		—		8.8
Shares purchased under share repurchase program	—	—		—		1.2	(297.6)		—		—		(297.6)

Dividends declared ($0.22 per share)	—	—		—		—	—		(15.9)		—		(15.9)
Other comprehensive loss, net of tax	—	—		—		—	—		—		(19.7)		(19.7)
Balance, March 31, 2026	75.3	$	18.8	$	—	4.4	$	(1,379.1)	$	4,475.9	$	(125.2)	$	2,990.4
Net income	—	—		—		—	—		154.0		—		154.0

Activity related to stock-based compensation	—	—		—		(0.1)	23.5		(5.8)		—		17.7
Shares purchased under share repurchase program	—	—		—		0.6	(156.7)		—		—		(156.7)


Other comprehensive loss, net of tax	—	—		—		—	—		—		(15.2)		(15.2)
Balance, June 30, 2026	75.3	$	18.8	$	—	4.9	$	(1,512.3)	$	4,624.1	$	(140.4)	$	2,990.2
Net income	—	—		—		—	—		214.0		—		214.0

Activity related to stock-based compensation	—	—		—		—	12.9		(6.1)		—		6.8
Shares purchased under share repurchase program	—	—		—		0.6	(231.0)		—		—		(231.0)
Dividends declared ($0.22 per share)	—	—		—		—	—		(15.2)		—		(15.2)
Other comprehensive income, net of tax	—	—		—		—	—		—		3.4		3.4
Balance, September 30, 2026	75.3	$	18.8	$	—	5.5	$	(1,730.4)	$	4,816.8	$	(137.0)	$	2,968.2

The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2025:


	Common Shares Issued	Common Stock		Capital in Excess of Par Value		Number of Treasury Shares	Treasury Stock		Retained earnings		Accumulated other comprehensive loss		Total
(in millions)
Balance, December 31, 2024	75.3	$	18.8	$	22.1	3.0	$	(1,057.1)	$	3,956.6	$	(258.1)	$	2,682.3
Net income	—	—		—		—	—		89.8		—		89.8
Activity related to stock-based compensation	—	—		(20.3)		(0.1)	27.4		—		—		7.1
Shares purchased under share repurchase program	—	—		—		0.6	(133.5)		—		—		(133.5)
Dividends declared ($0.21 per share)	—	—		—		—	—		(15.2)		—		(15.2)
Other comprehensive income, net of tax	—	—		—		—	—		—		52.6		52.6
Balance, March 31, 2025	75.3	$	18.8	$	1.8	3.5	$	(1,163.2)	$	4,031.2	$	(205.5)	$	2,683.1
Net income	—	—		—		—	—		131.8		—		131.8
Activity related to stock-based compensation	—	—		(1.8)		(0.1)	23.5		(8.8)		—		12.9
Shares purchased under share repurchase program	—	—		—		—	(0.5)		—		—		(0.5)


Dividends declared ($0.21 per share)	—	—		—		—	—		(15.0)		—		(15.0)
Other comprehensive income, net of tax	—	—		—		—	—		—		116.8		116.8
Balance, June 30, 2025	75.3	$	18.8	$	—	3.4	$	(1,140.2)	$	4,139.2	$	(88.7)	$	2,929.1
Net income	—	—		—		—	—		140.0		—		140.0
Activity related to stock-based compensation	—	—		—		—	12.8		(1.0)		—		11.8

Dividends declared ($0.22 per share)	—	—		—		—	—		(15.8)		—		(15.8)
Other comprehensive loss, net of tax	—	—		—		—	—		—		(13.6)		(13.6)
Balance, September 30, 2025	75.3	$	18.8	$	—	3.4	$	(1,127.4)	$	4,262.4	$	(102.3)	$	3,051.5

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481520/505-30-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.D.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.B.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

+ Details

Other Expense (Income) - Schedule of Other Expense (Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Other Income and Expenses [Abstract]
Restructuring and related charges	$ 3.9	$ 0.9	$ 8.0	$ 17.5
Gain on sale of SmartDose® 3.5mL, net	(55.7)	0.0	(55.7)	0.0
Contingent consideration	0.9	2.7	7.1	7.3
Asset impairments	0.4	0.3	4.6	1.4
Foreign exchange transaction losses	0.9	2.7	3.9	5.6
(Gain) loss on oil hedges	(2.0)	0.1	(2.9)	0.5
Other items	0.4	0.2	0.6	0.4
Total other expense (income)	$ (51.2)	$ 6.9	$ (34.4)	$ 32.7

Debt - Narrative (Details) - USD ($) $ in Thousands	Oct. 26, 2026	Sep. 30, 2026	Dec. 31, 2025
Debt Instrument [Line Items]
Long-term debt, gross		$ 203,000	$ 203,000
Term Loans
Debt Instrument [Line Items]
Long-term debt, gross		130,000
Revolving credit facility, Due 2024 \| Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, current borrowing capacity		500,000
Line of credit facility, unused commitment level		497,700
Revolving credit facility, Due 2024 \| Letter of Credit
Debt Instrument [Line Items]
Long-term line of credit		2,300
Line of Credit \| Revolving Credit Facility \| New Term Loan A \| Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 750,000
Line of Credit \| Revolving Credit Facility \| New Term Loan A \| Subsequent Event \| Minimum
Debt Instrument [Line Items]
Aggregate revolving commitments (as percent)	0.125%
Line of Credit \| Revolving Credit Facility \| New Term Loan A \| Subsequent Event \| Minimum \| Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Variable rate	1.00%
Line of Credit \| Revolving Credit Facility \| New Term Loan A \| Subsequent Event \| Minimum \| Base Rate
Debt Instrument [Line Items]
Variable rate	0.00%
Line of Credit \| Revolving Credit Facility \| New Term Loan A \| Subsequent Event \| Maximum
Debt Instrument [Line Items]
Aggregate revolving commitments (as percent)	0.225%
Line of Credit \| Revolving Credit Facility \| New Term Loan A \| Subsequent Event \| Maximum \| Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Variable rate	1.50%
Line of Credit \| Revolving Credit Facility \| New Term Loan A \| Subsequent Event \| Maximum \| Base Rate
Debt Instrument [Line Items]
Variable rate	0.50%
Unsecured Debt \| New Term Loan A \| Subsequent Event
Debt Instrument [Line Items]
Aggregate principal amount	$ 200,000
Net leverage ratio on acquisition periods	3.50
Material acquisition periods as maximum (as percent)	4.00
Unsecured Debt \| New Term Loan A \| Subsequent Event \| Minimum
Debt Instrument [Line Items]
Debt instrument, periodic payment	$ 1,250
Unsecured Debt \| New Term Loan A \| Subsequent Event \| Minimum \| Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Variable rate	1.125%
Unsecured Debt \| New Term Loan A \| Subsequent Event \| Minimum \| Base Rate
Debt Instrument [Line Items]
Variable rate	0.125%
Unsecured Debt \| New Term Loan A \| Subsequent Event \| Maximum
Debt Instrument [Line Items]
Debt instrument, periodic payment	$ 2,500
Unsecured Debt \| New Term Loan A \| Subsequent Event \| Maximum \| Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Variable rate	1.75%
Unsecured Debt \| New Term Loan A \| Subsequent Event \| Maximum \| Base Rate
Debt Instrument [Line Items]
Variable rate	0.75%
Term Loan, due July 2, 2027 (5.25%)
Debt Instrument [Line Items]
Long-term debt, gross		$ 130,000	130,000
Debt instrument, stated interest rate		5.25%
Series C notes, due July 5, 2027 (4.02%)
Debt Instrument [Line Items]
Long-term debt, gross		$ 73,000	$ 73,000
Debt instrument, stated interest rate		4.02%

Segment Information - Schedule of Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2025
Segment Reporting [Line Items]
Assets	$ 4,060.7		$ 4,060.7		$ 4,270.0
Depreciation and Amortization	45.9	$ 43.0	137.3	$ 124.4
Capital Expenditures	39.1	63.3	125.0	209.8
Net sales	874.5	804.6	2,591.7	2,269.1
Cost of goods and services sold	527.1	510.3	1,618.7	1,469.0
Research and development	18.3	17.1	53.8	52.5
Selling, general and administrative expenses	112.9	102.7	330.0	286.6
Operating profit	267.4	167.6	623.6	428.3
Stock-based compensation			(21.8)	(17.1)
Cost-method investment activity	0.0	0.0	(3.5)	0.0
Other	(0.4)	(0.2)	(0.6)	(0.4)
Interest (income) expense and other nonoperating expense (income), net	(0.3)	(4.3)	(4.3)	(11.1)
Income before income taxes and equity in net income of affiliated companies	267.7	171.9	627.9	439.4
Proprietary Products
Segment Reporting [Line Items]
Net sales	728.8	647.5	2,145.7	1,830.3
West Vantage
Segment Reporting [Line Items]
Net sales	145.7	157.1	446.0	438.8
Operating Segments
Segment Reporting [Line Items]
Net sales	874.5	804.6	2,591.7	2,269.1
Operating profit	246.1	197.5	675.7	521.1
Operating Segments \| Proprietary Products
Segment Reporting [Line Items]
Assets	2,925.2		2,925.2		2,987.0
Depreciation and Amortization	37.6	35.1	110.3	101.5
Capital Expenditures	28.6	47.7	100.5	148.1
Net sales	728.8	647.5	2,145.7	1,830.3
Cost of goods and services sold	405.4	383.5	1,241.2	1,107.8
Research and development	18.3	17.1	53.8	52.5
Selling, general and administrative expenses	74.5	65.6	209.0	187.4
Other segment expense (income)	0.0	6.1	10.0	15.1
Operating profit	230.6	175.2	631.7	467.5
Operating Segments \| West Vantage
Segment Reporting [Line Items]
Assets	696.8		696.8		718.1
Depreciation and Amortization	7.5	7.1	24.7	20.3
Capital Expenditures	8.2	13.6	18.9	57.2
Net sales	145.7	157.1	446.0	438.8
Cost of goods and services sold	121.7	126.8	377.5	361.2
Research and development	0.0	0.0	0.0	0.0
Selling, general and administrative expenses	8.1	7.5	24.2	22.1
Other segment expense (income)	0.4	0.5	0.3	1.9
Operating profit	15.5	22.3	44.0	53.6
Corporate And Reconciling Items
Segment Reporting [Line Items]
Assets	438.7		438.7		$ 564.9
Depreciation and Amortization	0.8	0.8	2.3	2.6
Capital Expenditures	2.3	2.0	5.6	4.5
Stock-based compensation	(4.3)	(8.4)	(21.8)	(17.1)
Corporate general costs	(20.3)	(19.0)	(54.0)	(53.6)
Restructuring and other charges	(6.3)	(2.5)	(9.3)	(21.9)
M&A activities, including SmartDose® 3.5mL sale	54.0	0.0	45.7	0.0
Cost-method investment activity			(3.5)	0.0
Amortization of acquisition-related intangible assets		(0.0)	0.0	(0.2)
Other	$ (1.8)	$ 0.0	$ (9.2)	$ 0.0

Revenue (Tables)

9 Months Ended

Sep. 30, 2026

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table presents the approximate percentage of our net sales by market group:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Biologics	43 %	41 %	43 %	39 %
Generics	15 %	17 %	15 %	17 %
Pharma	25 %	22 %	25 %	25 %
West Vantage	17 %	20 %	17 %	19 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by product category:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
High-Value Product ("HVP") Components	53 %	48 %	50 %	47 %
High-Value Product ("HVP") Delivery Devices	11 %	12 %	14 %	13 %
Standard Packaging	19 %	20 %	19 %	21 %
West Vantage	17 %	20 %	17 %	19 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by geographic location:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Americas	46 %	47 %	45 %	47 %
Europe, Middle East, Africa	43 %	45 %	45 %	45 %
Asia Pacific	11 %	8 %	10 %	8 %
	100 %	100 %	100 %	100 %

Schedule of Change in Contract with Customer, Asset and Liability

The following table summarizes our contract assets and liabilities:


	($ in millions)
Contract assets, December 31, 2025	$	11.9
Contract assets, September 30, 2026	15.1
Change in contract assets - increase (decrease)	$	3.2

Deferred income, December 31, 2025	$	(53.7)
Deferred income, September 30, 2026	(43.7)
Change in deferred income - decrease (increase)	$	10.0

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2026
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items. The provision for income taxes was $58.0 million and $34.0 million for the three months ended September 30, 2026 and 2025, respectively, and the effective tax rate was 21.7% and 19.8%, respectively. The increase in the effective tax rate for the three months ended September 30, 2026, as compared to the same period in 2025, is primarily due to a one-time tax cost of $22.4 million associated with the sale of SmartDose® 3.5mL On-Body Delivery System which occurred in the third quarter of 2026, partially offset by the impact of favorable changes in our geographic mix of earnings. The provision for income taxes was $134.9 million and $88.3 million for the nine months ended September 30, 2026 and 2025, respectively, and the effective tax rate was 21.5% and 20.1%, respectively. The increase in the effective tax rate for the nine months ended September 30, 2026, as compared to the same period in 2025, is primarily due to a one-time tax cost of $12.0 million associated with an internal legal entity restructuring which occurred in the first quarter of 2026, in addition to a one-time cost of $22.4 million associated with the sale of SmartDose® 3.5mL On-Body Delivery System which occurred in the third quarter of 2026, partially offset by the impact of favorable changes in our geographic mix of earnings. The liability for unrecognized tax benefits was $70.6 million and $56.1 million as of September 30, 2026 and December 31, 2025, respectively, and is included within other long-term liabilities.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2026

Equity [Abstract]

Schedule of Stockholders Equity

The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2026:


	Common Shares Issued	Common Stock		Capital in Excess of Par Value		Number of Treasury Shares	Treasury Stock		Retained earnings		Accumulated other comprehensive loss		Total
(in millions)
Balance, December 31, 2025	75.3	$	18.8	$	—	3.3	$	(1,112.2)	$	4,374.9	$	(105.5)	$	3,176.0
Net income	—	—		—		—	—		138.8		—		138.8

Activity related to stock-based compensation	—	—		—		(0.1)	30.7		(21.9)		—		8.8
Shares purchased under share repurchase program	—	—		—		1.2	(297.6)		—		—		(297.6)

Dividends declared ($0.22 per share)	—	—		—		—	—		(15.9)		—		(15.9)
Other comprehensive loss, net of tax	—	—		—		—	—		—		(19.7)		(19.7)
Balance, March 31, 2026	75.3	$	18.8	$	—	4.4	$	(1,379.1)	$	4,475.9	$	(125.2)	$	2,990.4
Net income	—	—		—		—	—		154.0		—		154.0

Activity related to stock-based compensation	—	—		—		(0.1)	23.5		(5.8)		—		17.7
Shares purchased under share repurchase program	—	—		—		0.6	(156.7)		—		—		(156.7)


Other comprehensive loss, net of tax	—	—		—		—	—		—		(15.2)		(15.2)
Balance, June 30, 2026	75.3	$	18.8	$	—	4.9	$	(1,512.3)	$	4,624.1	$	(140.4)	$	2,990.2
Net income	—	—		—		—	—		214.0		—		214.0

Activity related to stock-based compensation	—	—		—		—	12.9		(6.1)		—		6.8
Shares purchased under share repurchase program	—	—		—		0.6	(231.0)		—		—		(231.0)
Dividends declared ($0.22 per share)	—	—		—		—	—		(15.2)		—		(15.2)
Other comprehensive income, net of tax	—	—		—		—	—		—		3.4		3.4
Balance, September 30, 2026	75.3	$	18.8	$	—	5.5	$	(1,730.4)	$	4,816.8	$	(137.0)	$	2,968.2

The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2025:


	Common Shares Issued	Common Stock		Capital in Excess of Par Value		Number of Treasury Shares	Treasury Stock		Retained earnings		Accumulated other comprehensive loss		Total
(in millions)
Balance, December 31, 2024	75.3	$	18.8	$	22.1	3.0	$	(1,057.1)	$	3,956.6	$	(258.1)	$	2,682.3
Net income	—	—		—		—	—		89.8		—		89.8
Activity related to stock-based compensation	—	—		(20.3)		(0.1)	27.4		—		—		7.1
Shares purchased under share repurchase program	—	—		—		0.6	(133.5)		—		—		(133.5)
Dividends declared ($0.21 per share)	—	—		—		—	—		(15.2)		—		(15.2)
Other comprehensive income, net of tax	—	—		—		—	—		—		52.6		52.6
Balance, March 31, 2025	75.3	$	18.8	$	1.8	3.5	$	(1,163.2)	$	4,031.2	$	(205.5)	$	2,683.1
Net income	—	—		—		—	—		131.8		—		131.8
Activity related to stock-based compensation	—	—		(1.8)		(0.1)	23.5		(8.8)		—		12.9
Shares purchased under share repurchase program	—	—		—		—	(0.5)		—		—		(0.5)


Dividends declared ($0.21 per share)	—	—		—		—	—		(15.0)		—		(15.0)
Other comprehensive income, net of tax	—	—		—		—	—		—		116.8		116.8
Balance, June 30, 2025	75.3	$	18.8	$	—	3.4	$	(1,140.2)	$	4,139.2	$	(88.7)	$	2,929.1
Net income	—	—		—		—	—		140.0		—		140.0
Activity related to stock-based compensation	—	—		—		—	12.8		(1.0)		—		11.8

Dividends declared ($0.22 per share)	—	—		—		—	—		(15.8)		—		(15.8)
Other comprehensive loss, net of tax	—	—		—		—	—		—		(13.6)		(13.6)
Balance, September 30, 2025	75.3	$	18.8	$	—	3.4	$	(1,127.4)	$	4,262.4	$	(102.3)	$	3,051.5

Revenue - Schedule of Disaggregation of Revenue (Details) - Revenue Benchmark	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	100.00%	100.00%	100.00%	100.00%
Customer Concentration Risk \| Biologics
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	43.00%	41.00%	43.00%	39.00%
Customer Concentration Risk \| Generics
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	15.00%	17.00%	15.00%	17.00%
Customer Concentration Risk \| Pharma
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	25.00%	22.00%	25.00%	25.00%
Customer Concentration Risk \| West Vantage
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	17.00%	20.00%	17.00%	19.00%
Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	100.00%	100.00%	100.00%	100.00%
Product Concentration Risk \| High-Value Product ("HVP") Components
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	53.00%	48.00%	50.00%	47.00%
Product Concentration Risk \| High-Value Product ("HVP") Delivery Devices
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	11.00%	12.00%	14.00%	13.00%
Product Concentration Risk \| Standard Packaging
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	19.00%	20.00%	19.00%	21.00%
Product Concentration Risk \| West Vantage
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	17.00%	20.00%	17.00%	19.00%
Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	100.00%	100.00%	100.00%	100.00%
Geographic Concentration Risk \| Americas
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	46.00%	47.00%	45.00%	47.00%
Geographic Concentration Risk \| Europe, Middle East, Africa
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	43.00%	45.00%	45.00%	45.00%
Geographic Concentration Risk \| Asia Pacific
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	11.00%	8.00%	10.00%	8.00%

Segment Information (Tables)

9 Months Ended

Sep. 30, 2026

Segment Reporting [Abstract]

Schedule of Sales by Significant Product Group

The following table presents information about our reportable segments, reconciled to consolidated totals:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Net sales:
Proprietary Products	$	728.8	$	647.5	$	2,145.7	$	1,830.3
West Vantage	145.7		157.1		446.0		438.8

Consolidated net sales	$	874.5	$	804.6	$	2,591.7	$	2,269.1

Schedule of Segment Financial Information

The following tables provide summarized financial information for our two reportable segments and corporate and unallocated:


($ in millions)	September 30, 2026		December 31, 2025
Assets
Proprietary Products	$	2,925.2	$	2,987.0
West Vantage	696.8		718.1
Corporate and Unallocated (1)	438.7		564.9
Total consolidated	$	4,060.7	$	4,270.0


($ in millions)	Three Months Ended September 30,				Nine Months Ended September 30,
Depreciation and Amortization	2026		2025		2026		2025
Proprietary Products	$	37.6	$	35.1	$	110.3	$	101.5
West Vantage	7.5		7.1		24.7		20.3
Corporate and Unallocated	0.8		0.8		2.3		2.6
Total consolidated	$	45.9	$	43.0	$	137.3	$	124.4


($ in millions)	Three Months Ended September 30,				Nine Months Ended September 30,
Capital Expenditures	2026		2025		2026		2025
Proprietary Products	$	28.6	$	47.7	$	100.5	$	148.1
West Vantage	8.2		13.6		18.9		57.2
Corporate and Unallocated	2.3		2.0		5.6		4.5
Total consolidated	$	39.1	$	63.3	$	125.0	$	209.8

The following table provides summarized financial information for our segments:


	Three months ended September 30, 2026						Three months ended September 30, 2025
($ in millions)	Proprietary Products		West Vantage		Total		Proprietary Products		West Vantage		Total
Net sales	$	728.8	$	145.7	$	874.5	$	647.5	$	157.1	$	804.6
Cost of goods and services sold	405.4		121.7				383.5		126.8
Research and development	18.3		—				17.1		—
Selling, general and administrative expenses	74.5		8.1				65.6		7.5
Other segment expense (income)(1)	—		0.4				6.1		0.5
Segment operating profit	$	230.6	$	15.5	$	246.1	$	175.2	$	22.3	$	197.5
Reconciliation of profit or loss:
Stock-based compensation					(4.3)						(8.4)
Corporate general costs(2)					(20.3)						(19.0)
Unallocated items:
Restructuring and other charges(3)					(6.3)						(2.5)

M&A activities, including SmartDose® 3.5mL sale(4)					54.0						—



Other(7)					(1.8)						—
Total consolidated operating profit					267.4						167.6
Interest (income) expense and other nonoperating expense (income), net					(0.3)						(4.3)
Income before income taxes and equity in net income of affiliated companies					$	267.7					$	171.9


	Nine Months ended September 30, 2026						Nine months ended September 30, 2025
($ in millions)	Proprietary Products		West Vantage		Total		Proprietary Products		West Vantage		Total
Net sales	$	2,145.7	$	446.0	$	2,591.7	$	1,830.3	$	438.8	$	2,269.1
Cost of goods and services sold	1,241.2		377.5				1,107.8		361.2
Research and development	53.8		—				52.5		—
Selling, general and administrative expenses	209.0		24.2				187.4		22.1
Other segment expense (income)(1)	10.0		0.3				15.1		1.9
Segment operating profit	$	631.7	$	44.0	$	675.7	$	467.5	$	53.6	$	521.1
Reconciliation of profit or loss:
Stock-based compensation					(21.8)						(17.1)
Corporate general costs(2)					(54.0)						(53.6)
Unallocated items:
Restructuring and other charges(3)					(9.3)						(21.9)

M&A activities, including SmartDose® 3.5mL sale(4)					45.7						—
Cost-method investment activity(5)					(3.5)						—

Amortization of acquisition-related intangible assets(6)					—						(0.2)
Other(7)					(9.2)						—

Total consolidated operating profit					623.6						428.3
Interest (income) expense and other nonoperating expense (income), net					(4.3)						(11.1)
Income before income taxes and equity in net income of affiliated companies					$	627.9					$	439.4

(5) During the nine months ended September 30, 2026, the Company recorded cost-method investment impairment charges of $3.5 million within other expense (income).

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares shares in Millions	Sep. 30, 2026	Dec. 31, 2025
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	3.0	3.0
Preferred stock, shares issued (in shares)	0.0	0.0
Preferred stock, shares outstanding (in shares)	0.0	0.0
Common stock, par value (in dollars per share)	$ 0.25	$ 0.25
Common stock, shares authorized (in shares)	200.0	200.0
Common stock, shares issued (in shares)	75.3	75.3
Common stock, shares outstanding (in shares)	69.8	72.0
Treasury stock, at cost (in shares)	5.5	3.3

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References + Details

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References + Details

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Debt (Tables)

9 Months Ended

Sep. 30, 2026

Debt Disclosure [Abstract]

Schedule of Long-term Debt Obligations, Net of Current Maturities

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2026.


($ in millions)	September 30, 2026		December 31, 2025
Term Loan, due July 2, 2027 (5.25%)	$	130.0	$	130.0
Series C notes, due July 5, 2027 (4.02%)	73.0		73.0
	203.0		203.0
Less: unamortized debt issuance costs for Term Loan and Series Notes	0.1		0.2
Total debt	202.9		202.8
Less: current portion of long-term debt	—		—
Long-term debt, net	$	202.9	$	202.8

Accumulated Other Comprehensive Loss (Tables)

9 Months Ended

Sep. 30, 2026

Equity [Abstract]

Schedule of Components of Accumulated Other Comprehensive Loss

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2026:


($ in millions)	Derivatives		Change in equity affiliate investment AOCI		Defined benefit pension and other postretirement plans		Foreign currency translation		Total
Balance, December 31, 2025	$	(1.5)	$	3.2	$	(8.1)	$	(99.1)	$	(105.5)
Other comprehensive income (loss) before reclassifications	(1.7)		—		—		(32.1)		(33.8)
Amounts reclassified out from accumulated other comprehensive income (loss)	2.6		—		(0.3)		—		2.3
Other comprehensive income (loss), net of tax	0.9		—		(0.3)		(32.1)		(31.5)
Balance, September 30, 2026	$	(0.6)	$	3.2	$	(8.4)	$	(131.2)	$	(137.0)

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2025:


($ in millions)	Derivatives		Change in equity affiliate investment AOCI		Defined benefit pension and other postretirement plans		Foreign currency translation		Total
Balance, December 31, 2024	$	(2.5)	$	2.5	$	(9.8)	$	(248.3)	$	(258.1)
Other comprehensive income (loss) before reclassifications	3.2		0.1		(0.6)		153.3		156.0
Amounts reclassified out from accumulated other comprehensive income (loss)	0.2		—		(0.4)		—		(0.2)
Other comprehensive income (loss), net of tax	3.4		0.1		(1.0)		153.3		155.8
Balance, September 30, 2025	$	0.9	$	2.6	$	(10.8)	$	(95.0)	$	(102.3)

Schedule of Reclassification out of Accumulated Other Comprehensive Loss

A summary of the reclassifications out from accumulated other comprehensive loss is presented in the following table:


($ in millions)	Three Months Ended September 30,				Nine Months Ended September 30,
Detail of components	2026		2025		2026		2025		Location on Statement of Income
(Losses) gains on derivatives:
Foreign currency contracts	$	—	$	(0.4)	$	(0.4)	$	(0.5)	Net sales
Foreign currency contracts	(1.3)		0.5		(2.9)		0.2		Cost of goods and services sold

Forward treasury locks	(0.1)		—		(0.1)		(0.1)		Interest expense
Total before tax	(1.4)		0.1		(3.4)		(0.4)
Tax benefit	0.3		—		0.8		0.2
Net of tax	$	(1.1)	$	0.1	$	(2.6)	$	(0.2)
Amortization of defined benefit pension and other postretirement plans:


Actuarial gains	$	0.1	$	0.2	$	0.2	$	0.5	(a)

Other	0.1		—		0.2		—
Total before tax	0.2		0.2		0.4		0.5
Tax expense	(0.1)		—		(0.1)		(0.1)
Net of tax	$	0.1	$	0.2	$	0.3	$	0.4
Total reclassifications for the period, net of tax	$	(1.0)	$	0.3	$	(2.3)	$	0.2

(a) This component is included in the computation of net periodic benefit cost.

Other Expense (Income) (Tables)

9 Months Ended

Sep. 30, 2026

Other Income and Expenses [Abstract]

Schedule of Other Expense (Income)

Other expense (income) consists of:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Restructuring and related charges	$	3.9	$	0.9	$	8.0	$	17.5
Gain on sale of SmartDose® 3.5mL, net	(55.7)		—		(55.7)		—
Contingent consideration	0.9		2.7		7.1		7.3
Asset impairments	0.4		0.3		4.6		1.4
Foreign exchange transaction losses	0.9		2.7		3.9		5.6
(Gain) loss on oil hedges	(2.0)		0.1		(2.9)		0.5
Other items	0.4		0.2		0.6		0.4
Total other expense (income)	$	(51.2)	$	6.9	$	(34.4)	$	32.7

Schedule of Restructuring Reserve

The following table presents activity related to our restructuring obligations related to our January 2025 restructuring plan:


($ in millions)	Severance and benefits		Asset-related charges		Total
Balance, December 31, 2025	$	6.9	$	—	$	6.9
Charges (Credits)	3.8		3.8		7.6
Cash payments	(0.2)		—		(0.2)
Non-cash asset write downs	—		(3.8)		(3.8)
Balance, September 30, 2026	$	10.5	$	—	$	10.5

The following table presents activity related to our restructuring obligations related to our December 2025 restructuring plan:


($ in millions)	Severance and benefits		Total
Balance, December 31, 2025	$	4.2	$	4.2
Charges (Credits)	0.4		0.4
Cash payments	(2.7)		(2.7)

Balance, September 30, 2026	$	1.9	$	1.9

Schedule of Asset Impairment Charges

During the periods ended September 30, asset impairments consisted of:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025

Cost-method investment impairment charges	$	—	$	—	$	3.5	$	—
Fixed asset impairment expense	0.4		0.3		1.1		1.4
Total asset impairments	$	0.4	$	0.3	$	4.6	$	1.4

Affiliated Companies - Schedule of Company's Affiliate Transactions (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Schedule of Equity Method Investments [Line Items]
Purchases from (and payments to) affiliates	$ 38.0	$ 25.2	$ 106.3	$ 83.1
Sales to affiliates	874.5	804.6	2,591.7	2,269.1
Affiliated Entity
Schedule of Equity Method Investments [Line Items]
Sales to affiliates	$ 5.9	$ 3.4	$ 13.6	$ 9.4

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Other Expense (Income) - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Restructuring Reserve [Roll Forward]
Non-cash asset write downs	$ (3.8)	$ (2.5)
January 2025 Restructuring Plan
Restructuring Reserve [Roll Forward]
Balance, December 31, 2025	6.9
Charges (Credits)	7.6
Cash payments	(0.2)
Non-cash asset write downs	(3.8)
Balance, September 30, 2026	10.5
December 2025 Restructuring Plan
Restructuring Reserve [Roll Forward]
Balance, December 31, 2025	4.2
Charges (Credits)	0.4
Cash payments	(2.7)
Balance, September 30, 2026	1.9
Severance and benefits \| January 2025 Restructuring Plan
Restructuring Reserve [Roll Forward]
Balance, December 31, 2025	6.9
Charges (Credits)	3.8
Cash payments	(0.2)
Non-cash asset write downs	0.0
Balance, September 30, 2026	10.5
Severance and benefits \| December 2025 Restructuring Plan
Restructuring Reserve [Roll Forward]
Balance, December 31, 2025	4.2
Charges (Credits)	0.4
Cash payments	(2.7)
Balance, September 30, 2026	1.9
Asset-related charges \| January 2025 Restructuring Plan
Restructuring Reserve [Roll Forward]
Balance, December 31, 2025	0.0
Charges (Credits)	3.8
Cash payments	0.0
Non-cash asset write downs	(3.8)
Balance, September 30, 2026	$ 0.0

- Definition

Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.

+ References + Details

Other Expense (Income) - Schedule of Asset Impairment Charges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Restructuring and Related Activities [Abstract]
Cost-method investment impairment charges	$ 0.0	$ 0.0	$ 3.5	$ 0.0
Fixed asset impairment expense	0.4	0.3	1.1	1.4
Total asset impairments	$ 0.4	$ 0.3	$ 4.6	$ 1.4

Accumulated Other Comprehensive Loss - Schedule of Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 2,990.2	$ 2,990.4	$ 3,176.0	$ 2,929.1	$ 2,683.1	$ 2,682.3	$ 3,176.0	$ 2,682.3
Other comprehensive income (loss) before reclassifications							(33.8)	156.0
Amounts reclassified out from accumulated other comprehensive income (loss)							2.3	(0.2)
Other comprehensive income (loss), net of tax	3.4	(15.2)	(19.7)	(13.6)	116.8	52.6	(31.5)	155.8
Ending balance	2,968.2	2,990.2	2,990.4	3,051.5	2,929.1	2,683.1	2,968.2	3,051.5
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(140.4)	(125.2)	(105.5)	(88.7)	(205.5)	(258.1)	(105.5)	(258.1)
Other comprehensive income (loss), net of tax	3.4	(15.2)	(19.7)	(13.6)	116.8	52.6
Ending balance	(137.0)	$ (140.4)	(125.2)	(102.3)	$ (88.7)	(205.5)	(137.0)	(102.3)
Derivatives
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			(1.5)			(2.5)	(1.5)	(2.5)
Other comprehensive income (loss) before reclassifications							(1.7)	3.2
Amounts reclassified out from accumulated other comprehensive income (loss)							2.6	0.2
Other comprehensive income (loss), net of tax							0.9	3.4
Ending balance	(0.6)			0.9			(0.6)	0.9
Change in equity affiliate investment AOCI
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			3.2			2.5	3.2	2.5
Other comprehensive income (loss) before reclassifications							0.0	0.1
Amounts reclassified out from accumulated other comprehensive income (loss)							0.0	0.0
Other comprehensive income (loss), net of tax							0.0	0.1
Ending balance	3.2			2.6			3.2	2.6
Defined benefit pension and other postretirement plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			(8.1)			(9.8)	(8.1)	(9.8)
Other comprehensive income (loss) before reclassifications							0.0	(0.6)
Amounts reclassified out from accumulated other comprehensive income (loss)							(0.3)	(0.4)
Other comprehensive income (loss), net of tax							(0.3)	(1.0)
Ending balance	(8.4)			(10.8)			(8.4)	(10.8)
Foreign currency translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			$ (99.1)			$ (248.3)	(99.1)	(248.3)
Other comprehensive income (loss) before reclassifications							(32.1)	153.3
Amounts reclassified out from accumulated other comprehensive income (loss)							0.0	0.0
Other comprehensive income (loss), net of tax							(32.1)	153.3
Ending balance	$ (131.2)			$ (95.0)			$ (131.2)	$ (95.0)

Segment Information - Schedule of Sales by Significant Product Group (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Segment Reporting [Line Items]
Net sales	$ 874.5	$ 804.6	$ 2,591.7	$ 2,269.1
Proprietary Products
Segment Reporting [Line Items]
Net sales	728.8	647.5	2,145.7	1,830.3
West Vantage
Segment Reporting [Line Items]
Net sales	$ 145.7	$ 157.1	$ 446.0	$ 438.8

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (j)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

Debt - Schedule of Long-term Debt Obligations, Net of Current Maturities (Details) - USD ($) $ in Millions	Sep. 30, 2026	Dec. 31, 2025
Debt Instrument [Line Items]
Long-term debt, gross	$ 203.0	$ 203.0
Less: unamortized debt issuance costs for Term Loan and Series Notes	0.1	0.2
Total debt	202.9	202.8
Less: current portion of long-term debt	0.0	0.0
Long-term debt, net	$ 202.9	202.8
Term Loan, due July 2, 2027 (5.25%)
Debt Instrument [Line Items]
Debt instrument, stated interest rate	5.25%
Long-term debt, gross	$ 130.0	130.0
Series C notes, due July 5, 2027 (4.02%)
Debt Instrument [Line Items]
Debt instrument, stated interest rate	4.02%
Long-term debt, gross	$ 73.0	$ 73.0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 26: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

+ Details

Affiliated Companies (Tables)

9 Months Ended

Sep. 30, 2026

Equity Method Investments and Joint Ventures [Abstract]

Schedule of Aggregate Carrying Amount and Amounts Due to Affiliates in the Condensed Consolidated Balance Sheets and Company's Affiliate Transactions

The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:


	September 30,		December 31,
($ in millions)	2026		2025
Aggregate carrying value of investments in affiliated companies:
Equity method affiliates	$	215.2	$	208.3
Non-equity method affiliates	0.6		4.0
Total investments in affiliated companies	$	215.8	$	212.3

The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:


	September 30,		December 31,
($ in millions)	2026		2025
Payables due to affiliates	$	34.2	$	26.2
Receivables due from affiliates	$	3.6	$	2.0

The following table summarizes the Company's affiliate transactions:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Purchases from (and payments to) affiliates	$	38.0	$	25.2	$	106.3	$	83.1
Sales to affiliates	$	5.9	$	3.4	$	13.6	$	9.4

Leases - Schedule of Lease Cash Flow and Supplemental Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 21.3	$ 19.6
Operating cash flows from finance leases	0.2	0.1
Financing cash flows from finance leases	1.2	0.8
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases	4.3	9.9
Finance leases	$ 5.2	$ 2.9

Derivative Financial Instruments

9 Months Ended

Sep. 30, 2026

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.

Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans in Singapore Dollar (“SGD”) and on cross-currency intercompany demand notes in Euro ("EUR"), which were executed at various times throughout 2025 and 2026. The following table summarizes the total amount of the following forward exchange contracts as fair value hedges at the following dates:


(in millions)		September 30,		December 31,
Forward Exchange Contracts	Currency	2026		2025
Cross-Currency Intercompany Loans	SGD	SGD	209.1	SGD	421.9

Cross-Currency Intercompany Demand Notes	EUR	€	23.5	€	23.5

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2026, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:


(in millions)		Sell
Currency	Purchase	USD	EUR
EUR	30.3	35.8	—
JPY	4,943.4	19.1	11.2
SGD	66.2	46.1	5.9

In July 2024, we entered into a cross-currency swap for $130 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2026, the notional amount of the cross-currency swap is ¥17.0 billion ($130.0 million), and the swap termination date is July 2, 2027. Under the cross-currency swap, we receive fixed USD interest rate payments in return for paying fixed JPY interest rate payments.

Additionally, we will periodically enter into forward exchange contracts to mitigate our exposure to fluctuating foreign exchange rates on assets and liabilities, other than the intercompany loans and demand notes referenced above, which are denominated in foreign currencies. The Company has elected not to designate these forward contracts in hedging relationships, and any change in the value of the contracts is recognized in income.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

We regularly purchase call options on crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. As of September 30, 2026, we had outstanding contracts to purchase 227,960 barrels of crude oil from September 2026 to March 2028, at a weighted-average strike price of $83.16 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2026 and December 31, 2025.

The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:


	Amount of Gain (Loss) Recognized in Income for the				Amount of Gain (Loss) Recognized in Income for the
	Three Months Ended September 30,				Nine Months Ended September 30,				Location on Statement of Income
($ in millions)	2026		2025		2026		2025
Fair Value Hedges:
Hedged item (intercompany loan)	$	(3.3)	$	3.9	$	(8.2)	$	7.3	Other expense (income)
Derivative designated as hedging instrument	3.3		(3.9)		8.2		(7.3)		Other expense (income)
Amount excluded from effectiveness testing	0.4		(0.4)		(0.5)		(1.3)		Other expense (income)
Total	$	0.4	$	(0.4)	$	(0.5)	$	(1.3)

We recognize in earnings the initial value of forward point components for hedges of intercompany loans on a straight-line basis over the life of the fair value hedge. The value of forward point components for hedges of intercompany demand notes is recognized currently in earnings using a market approach. The income recognized in earnings, pre-tax, for forward point components for the three months ended September 30, 2026 was $0.4 million. The expense recognized in earnings, pre-tax, for forward point components for the nine months ended September 30, 2026 was $0.5 million. The expense recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2025 was $0.4 million and $1.3 million, respectively.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:


	Amount of Gain (Loss) Recognized in OCI for the				Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the				Location of (Gain) Loss Reclassified from Accumulated OCI into Income
	Three Months Ended September 30,				Three Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Fair Value Hedges:
Foreign currency hedge contracts	$	(0.2)	$	0.2	$	—	$	—	Other expense (income)
Total	$	(0.2)	$	0.2	$	—	$	—
Cash Flow Hedges:
Foreign currency hedge contracts	$	0.8	$	0.8	$	(0.1)	$	0.3	Net sales
Foreign currency hedge contracts	0.2		(2.5)		1.1		(0.5)		Cost of goods and services sold

Forward treasury locks	—		—		0.1		0.1		Interest expense
Total	$	1.0	$	(1.7)	$	1.1	$	(0.1)
Net Investment Hedges:

Cross-currency swap	$	(3.0)	$	2.4	$	—	$	—	Other expense (income)
Total	$	(3.0)	$	2.4	$	—	$	—


	Amount of Gain (Loss) Recognized in OCI for the				Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the				Location of (Gain) Loss Reclassified from Accumulated OCI into Income
	Nine Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Fair Value Hedges:
Foreign currency hedge contracts	$	—	$	1.0	$	—	$	—	Other expense (income)
Total	$	—	$	1.0	$	—	$	—
Cash Flow Hedges:
Foreign currency hedge contracts	$	0.7	$	(1.8)	$	0.3	$	0.4	Net sales
Foreign currency hedge contracts	(2.4)		4.0		2.2		(0.3)		Cost of goods and services sold

Forward treasury locks	—		—		0.1		0.1		Interest expense
Total	$	(1.7)	$	2.2	$	2.6	$	0.2
Net Investment Hedges:

Cross-currency swap	$	(1.2)	$	(3.8)	$	—	$	—	Other expense (income)
Total	$	(1.2)	$	(3.8)	$	—	$	—

Refer to the above tables which summarize the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2026 and September 30, 2025.

The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in the condensed consolidated statements of income:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Net sales	$	(0.1)	$	0.3	$	0.3	$	0.4
Cost of goods and services sold	$	1.1	$	(0.5)	$	2.2	$	(0.3)
Interest expense	$	0.1	$	0.1	$	0.1	$	0.1

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:


	Amount of Gain (Loss) Recognized in Income for the				Amount of Gain (Loss) Recognized in Income for the
	Three Months Ended September 30,				Nine Months Ended September 30,				Location on Statement of Income
($ in millions)	2026		2025		2026		2025
Commodity call options	$	1.9	$	(0.1)	$	2.9	$	(0.5)	Other expense (income)
Currency Forwards	0.1		0.3		1.3		1.2		Other expense (income)
Total	$	2.0	$	0.2	$	4.2	$	0.7

For the three and nine months ended September 30, 2026 and 2025, there was no material ineffectiveness related to these hedges.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 181
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-181

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 184
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-184

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 185
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-185

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 15
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480960/815-15-50-3

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 183
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-183

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4F
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/815/tableOfContent

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C

+ Details

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2025
Income Tax Contingency [Line Items]
Provision for income taxes	$ 58.0		$ 34.0	$ 134.9	$ 88.3
Effective income tax rate (in percent)	21.70%		19.80%	21.50%	20.10%
Increase in the effective tax rate primarily due to a one-time tax cost associated with an internal legal entity restructuring		$ 12.0
Unrecognized tax benefits	$ 70.6			$ 70.6		$ 56.1
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| SmartDose® 3.5mL On-Body Delivery System And Associated Facilities
Income Tax Contingency [Line Items]
One time tax cost associated with sale	$ 22.4

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2026	Dec. 31, 2025
Inventory Disclosure [Abstract]
Raw materials	$ 170.1	$ 163.2
Work in process	95.4	103.2
Finished goods	199.2	177.5
Total inventories	$ 464.7	$ 443.9

Derivative Financial Instruments - Schedule of Derivative Instruments Not Designated as Hedges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	$ 2.0	$ (0.1)	$ 2.9	$ (0.5)
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	2.0	0.2	4.2	0.7
Commodity call options \| Not Designated as Hedging Instrument \| Income Statement Location [Axis]: wst:OtherIncomeExpense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	1.9	(0.1)	2.9	(0.5)
Currency Forwards \| Not Designated as Hedging Instrument \| Income Statement Location [Axis]: wst:OtherIncomeExpense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	$ 0.1	$ 0.3	$ 1.3	$ 1.2

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(6)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CC
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E

+ Details

Net Income Per Share - Schedule of Repurchase of Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended					9 Months Ended
	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
Earnings Per Share [Abstract]
Shares repurchased (in shares)	663,511					2,424,121	552,593
Total cost of repurchases ($ in millions)	$ 231.0	$ 156.7	$ 297.6	$ 0.5	$ 133.5	$ 685.3	$ 134.0
Average price per repurchased share (in dollars per share)	$ 348.11					$ 282.68	$ 242.55

- Definition

Number of shares that have been repurchased during the period and are being held in treasury.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

- Definition

Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.

+ References + Details

Leases - Schedule of Assets and Liabilities, Lessee (Details) - USD ($) $ in Millions	Sep. 30, 2026	Dec. 31, 2025
Leases [Abstract]
ROU assets, net	$ 37.5	$ 34.7
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other noncurrent assets
Lease liabilities (current)	$ 1.4	1.5
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities
Lease liabilities (noncurrent)	$ 7.5	$ 3.6
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities

Accumulated Other Comprehensive Loss - Schedule of Reclassification out of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Net sales	$ 874.5			$ 804.6			$ 2,591.7	$ 2,269.1
Cost of goods and services sold	(527.1)			(510.3)			(1,618.7)	(1,469.0)
Interest expense	(3.8)			(0.2)			(8.3)	(0.7)
Income before income taxes and equity in net income of affiliated companies	267.7			171.9			627.9	439.4
Tax benefit (expense)	(58.0)			(34.0)			(134.9)	(88.3)
Total reclassifications for the period, net of tax	214.0	$ 154.0	$ 138.8	140.0	$ 131.8	$ 89.8	506.8	361.6
Reclassification out of Accumulated Other Comprehensive Loss
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Total reclassifications for the period, net of tax	(1.0)			0.3			(2.3)	0.2
Reclassification out of Accumulated Other Comprehensive Loss \| (Losses) gains on derivatives:
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Income before income taxes and equity in net income of affiliated companies	(1.4)			0.1			(3.4)	(0.4)
Tax benefit (expense)	0.3			0.0			0.8	0.2
Total reclassifications for the period, net of tax	(1.1)			0.1			(2.6)	(0.2)
Reclassification out of Accumulated Other Comprehensive Loss \| Amortization of defined benefit pension and other postretirement plans:
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Actuarial gains	0.1			0.2			0.2	0.5
Other	0.1			0.0			0.2	0.0
Income before income taxes and equity in net income of affiliated companies	0.2			0.2			0.4	0.5
Tax benefit (expense)	(0.1)			0.0			(0.1)	(0.1)
Total reclassifications for the period, net of tax	0.1			0.2			0.3	0.4
Foreign currency contracts \| Reclassification out of Accumulated Other Comprehensive Loss \| (Losses) gains on derivatives:
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Net sales	0.0			(0.4)			(0.4)	(0.5)
Cost of goods and services sold	(1.3)			0.5			(2.9)	0.2
Forward treasury locks \| Reclassification out of Accumulated Other Comprehensive Loss \| (Losses) gains on derivatives:
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Interest expense	$ (0.1)			$ 0.0			$ (0.1)	$ (0.1)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Statement of Comprehensive Income [Abstract]
Foreign currency translation adjustments, tax	$ (0.9)	$ 0.7	$ (0.4)	$ (1.4)
Defined benefit pension and other postretirement plan adjustments, tax	(0.0)	(0.0)	(0.0)	(0.3)
Net gain (loss) on equity affiliate accumulated other comprehensive income, tax	0.0	0.0	0.0	0.0
Net gain (loss) on derivatives, tax	$ 0.6	$ (0.5)	$ 0.4	$ 1.2

Shareholder's Equity (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)			75,300,000				75,300,000
Beginning balance	$ 2,990.2	$ 2,990.4	$ 3,176.0	$ 2,929.1	$ 2,683.1	$ 2,682.3	$ 3,176.0	$ 2,682.3
Beginning balance (in shares)			3,300,000				3,300,000
Net income	214.0	154.0	$ 138.8	140.0	131.8	89.8	$ 506.8	$ 361.6
Activity related to stock-based compensation	$ 6.8	17.7	8.8	11.8	12.9	7.1
Shares purchased under share repurchase program (in shares)	663,511						2,424,121	552,593
Shares purchased under share repurchase program	$ (231.0)	(156.7)	(297.6)		(0.5)	(133.5)	$ (685.3)	$ (134.0)
Dividends declared	(15.2)		(15.9)	(15.8)	(15.0)	(15.2)
Other comprehensive income (loss), net of tax	$ 3.4	(15.2)	(19.7)	(13.6)	116.8	52.6	$ (31.5)	155.8
Ending balance (in shares)	75,300,000						75,300,000
Ending balance	$ 2,968.2	$ 2,990.2	$ 2,990.4	$ 3,051.5	$ 2,929.1	$ 2,683.1	$ 2,968.2	$ 3,051.5
Ending balance (in shares)	5,500,000						5,500,000
Dividends declared per share (in dollars per share)	$ 0.22		$ 0.22	$ 0.22	$ 0.21	$ 0.21
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000
Beginning balance	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8
Ending balance (in shares)	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000
Ending balance	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8
Capital in Excess of Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	0.0	0.0	0.0	0.0	1.8	22.1	0.0	22.1
Activity related to stock-based compensation					(1.8)	(20.3)
Ending balance	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ (1,512.3)	$ (1,379.1)	$ (1,112.2)	$ (1,140.2)	$ (1,163.2)	$ (1,057.1)	$ (1,112.2)	$ (1,057.1)
Beginning balance (in shares)	4,900,000	4,400,000	3,300,000	3,400,000	3,500,000	3,000,000.0	3,300,000	3,000,000.0
Activity related to stock-based compensation (in shares)		(100,000)	(100,000)		(100,000)	(100,000)
Activity related to stock-based compensation	$ 12.9	$ 23.5	$ 30.7	$ 12.8	$ 23.5	$ 27.4
Shares purchased under share repurchase program (in shares)	600,000	600,000	1,200,000			600,000
Shares purchased under share repurchase program	$ (231.0)	$ (156.7)	$ (297.6)		(0.5)	$ (133.5)
Ending balance	$ (1,730.4)	$ (1,512.3)	$ (1,379.1)	$ (1,127.4)	$ (1,140.2)	$ (1,163.2)	$ (1,730.4)	$ (1,127.4)
Ending balance (in shares)	5,500,000	4,900,000	4,400,000	3,400,000	3,400,000	3,500,000	5,500,000	3,400,000
Retained earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 4,624.1	$ 4,475.9	$ 4,374.9	$ 4,139.2	$ 4,031.2	$ 3,956.6	$ 4,374.9	$ 3,956.6
Net income	214.0	154.0	138.8	140.0	131.8	89.8
Activity related to stock-based compensation	(6.1)	(5.8)	(21.9)	(1.0)	(8.8)
Dividends declared	(15.2)		(15.9)	(15.8)	(15.0)	(15.2)
Ending balance	4,816.8	4,624.1	4,475.9	4,262.4	4,139.2	4,031.2	4,816.8	4,262.4
Accumulated other comprehensive loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(140.4)	(125.2)	(105.5)	(88.7)	(205.5)	(258.1)	(105.5)	(258.1)
Other comprehensive income (loss), net of tax	3.4	(15.2)	(19.7)	(13.6)	116.8	52.6
Ending balance	$ (137.0)	$ (140.4)	$ (125.2)	$ (102.3)	$ (88.7)	$ (205.5)	$ (137.0)	$ (102.3)

Leases - Schedule of Lease Terms and Discount Rates (Details)	Sep. 30, 2026	Dec. 31, 2025
Weighted average remaining lease term (in years):
Operating leases	8 years 2 months 12 days	8 years 3 months 18 days
Finance leases	3 years 10 months 24 days	4 years 4 months 24 days
Weighted average discount rate:
Operating leases	4.82%	4.67%
Finance leases	4.76%	4.15%

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Sep. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 464.1	$ 791.3
Accounts receivable, net	748.2	574.4
Inventories	464.7	443.9
Other current assets	139.5	168.6
Total current assets	1,816.5	1,978.2
Property, plant and equipment	3,266.1	3,223.4
Less: accumulated depreciation and amortization	1,594.1	1,497.0
Property, plant and equipment, net	1,672.0	1,726.4
Operating lease right-of-use assets	98.4	117.0
Investments in affiliated companies	215.8	212.3
Goodwill	108.7	109.9
Intangible assets, net	6.2	7.7
Deferred income taxes	60.2	38.4
Other noncurrent assets	82.9	80.1
Total Assets	4,060.7	4,270.0
Current liabilities:
Accounts payable	249.4	253.7
Accrued salaries, wages and benefits	124.3	135.9
Income taxes payable	56.2	28.1
Operating lease liabilities	19.5	22.7
Accrued commissions, rebates and royalties	38.6	39.2
Other current liabilities	156.3	175.3
Total current liabilities	644.3	654.9
Long-term debt	202.9	202.8
Deferred income taxes	23.0	23.0
Pension and other postretirement benefits	28.6	29.0
Operating lease liabilities	82.6	95.6
Deferred compensation benefits	14.0	13.5
Other long-term liabilities	97.1	75.2
Total Liabilities	1,092.5	1,094.0
Commitments and contingencies (Note 16)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding	0.0	0.0
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: September 30, 2026 - 75.3 million, December 31, 2025 - 75.3 million; shares outstanding: September 30, 2026 - 69.8 million, December 31, 2025 - 72.0 million	18.8	18.8
Capital in excess of par value	0.0	0.0
Retained earnings	4,816.8	4,374.9
Accumulated other comprehensive loss	(137.0)	(105.5)
Treasury stock, at cost (September 30, 2026 - 5.5 million shares, December 31, 2025 - 3.3 million shares)	(1,730.4)	(1,112.2)
Total Equity	2,968.2	3,176.0
Total Liabilities and Equity	$ 4,060.7	$ 4,270.0

Segment Information - Narrative (Details)	9 Months Ended
Segment Information - Narrative (Details)	Sep. 30, 2026 segment
Segment Reporting [Abstract]
Number of reportable segments	2

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Income Statement [Abstract]
Net sales	$ 874.5	$ 804.6	$ 2,591.7	$ 2,269.1
Cost of goods and services sold	527.1	510.3	1,618.7	1,469.0
Gross profit	347.4	294.3	973.0	800.1
Research and development	18.3	17.1	53.8	52.5
Selling, general and administrative expenses	112.9	102.7	330.0	286.6
Other expense (income) (Note 14)	(51.2)	6.9	(34.4)	32.7
Operating profit	267.4	167.6	623.6	428.3
Interest expense, net	3.8	0.2	8.3	0.7
Interest income	(4.3)	(4.7)	(13.2)	(12.4)
Other nonoperating expense (income)	0.2	0.2	0.6	0.6
Income before income taxes and equity in net income of affiliated companies	267.7	171.9	627.9	439.4
Income tax expense	58.0	34.0	134.9	88.3
Equity in net income of affiliated companies	(4.3)	(2.1)	(13.8)	(10.5)
Net income	$ 214.0	$ 140.0	$ 506.8	$ 361.6
Net income per share:
Basic (in dollars per share)	$ 3.04	$ 1.94	$ 7.13	$ 5.00
Diluted (in dollars per share)	$ 3.02	$ 1.92	$ 7.09	$ 4.97
Weighted average shares outstanding:
Basic (in shares)	70.4	72.2	71.1	72.3
Diluted (in shares)	70.8	72.6	71.5	72.7

Other Expense (Income)

9 Months Ended

Sep. 30, 2026

Other Income and Expenses [Abstract]

Other Expense (Income)

Other expense (income) consists of:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Restructuring and related charges	$	3.9	$	0.9	$	8.0	$	17.5
Gain on sale of SmartDose® 3.5mL, net	(55.7)		—		(55.7)		—
Contingent consideration	0.9		2.7		7.1		7.3
Asset impairments	0.4		0.3		4.6		1.4
Foreign exchange transaction losses	0.9		2.7		3.9		5.6
(Gain) loss on oil hedges	(2.0)		0.1		(2.9)		0.5
Other items	0.4		0.2		0.6		0.4
Total other expense (income)	$	(51.2)	$	6.9	$	(34.4)	$	32.7

Restructuring and Related Charges

In January 2025, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes were expected to be implemented over a period of approximately twenty-four to thirty-six months from the date of approval. In September 2026, the Company expanded the scope of the originally approved January 2025 plan to include additional manufacturing site consolidation., which is expected to require an incremental charge of $20 million, primarily representing additional accelerated depreciation and lease amortization charges. The new total charge for this plan is now $48 million to $50 million, approximately $26 million of which the Company has recognized through September 30, 2026. Annualized savings are in the range of $35 million to $40 million. The following table presents activity related to our restructuring obligations related to our January 2025 restructuring plan:


($ in millions)	Severance and benefits		Asset-related charges		Total
Balance, December 31, 2025	$	6.9	$	—	$	6.9
Charges (Credits)	3.8		3.8		7.6
Cash payments	(0.2)		—		(0.2)
Non-cash asset write downs	—		(3.8)		(3.8)
Balance, September 30, 2026	$	10.5	$	—	$	10.5

In December 2025, the Company approved a restructuring plan related to a definitive agreement to sell all manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. These changes are expected to be implemented over a period of approximately twelve to fifteen months from the date of approval. The plan is expected to require restructuring and related charges of $12 million to $16 million, with annualized savings in the range of $15 million to $20 million. The following table presents activity related to our restructuring obligations related to our December 2025 restructuring plan:


($ in millions)	Severance and benefits		Total
Balance, December 31, 2025	$	4.2	$	4.2
Charges (Credits)	0.4		0.4
Cash payments	(2.7)		(2.7)

Balance, September 30, 2026	$	1.9	$	1.9

Asset Impairments

The Company's asset impairment expense includes impairment charges to its cost-method investments and expense related to fixed assets impaired or taken out of service. During the periods ended September 30, asset impairments consisted of:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025

Cost-method investment impairment charges	$	—	$	—	$	3.5	$	—
Fixed asset impairment expense	0.4		0.3		1.1		1.4
Total asset impairments	$	0.4	$	0.3	$	4.6	$	1.4

COVER - shares	9 Months Ended
COVER - shares	Sep. 30, 2026	Oct. 21, 2026
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2026
Document Transition Report	false
Entity File Number	1-8036
Entity Registrant Name	WEST PHARMACEUTICAL SERVICES, INC.
Entity Incorporation, State or Country Code	PA
Entity Tax Identification Number	23-1210010
Entity Address, Address Line One	530 Herman O. West Drive
Entity Address, City or Town	Exton
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19341-1147
City Area Code	610
Local Phone Number	594-2900
Title of each class	Common Stock, par value $0.25 per share
Trading Symbol	WST
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		69,661,036
Entity Central Index Key	0000105770
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q3
Amendment Flag	false

Leases

9 Months Ended

Sep. 30, 2026

Leases [Abstract]

Leases

A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Operating lease cost	$	8.0	$	6.9	$	22.5	$	20.3
Finance lease - amortization of right-of-use (ROU) assets	0.4		0.5		1.4		1.2
Finance lease - interest on lease liabilities	0.1		—		0.2		0.1
Short-term lease cost	1.2		1.0		3.2		2.5
Variable lease cost	2.3		2.9		7.8		8.3
Total lease cost	$	12.0	$	11.3	$	35.1	$	32.4

The following table summarizes the finance lease amounts in the condensed consolidated balance sheets:



		September 30,		December 31,
($ in millions)	Balance Sheet Classification	2026		2025

ROU assets, net	Other noncurrent assets	$	37.5	$	34.7
Lease liabilities (current)	Other current liabilities	$	1.4	$	1.5
Lease liabilities (noncurrent)	Other long-term liabilities	$	7.5	$	3.6

Supplemental cash flow information related to leases was as follows:


	Nine Months Ended September 30,
($ in millions)		2026		2025
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		$	21.3	$	19.6
Operating cash flows from finance leases		$	0.2	$	0.1
Financing cash flows from finance leases		$	1.2	$	0.8
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases		$	4.3	$	9.9
Finance leases		$	5.2	$	2.9

The following table shows the weighted average remaining lease terms and discount rates for our operating and finance leases as of the periods ended:


	September 30, 2026		December 31, 2025
Weighted average remaining lease term (in years):
Operating leases	8.2		8.3
Finance leases	3.9		4.4
Weighted average discount rate:
Operating leases	4.82	%	4.67	%
Finance leases	4.76	%	4.15	%

Maturities of the Company's lease liabilities as of September 30, 2026 were as follows:


($ in millions)
Year	Operating Leases		Finance Leases
2026 (remaining period as of September 30, 2026)	$	6.9	$	0.4
2027	23.1		1.5
2028	21.0		1.3
2029	15.5		0.8
2030	8.3		5.7
Thereafter	51.6		0.5
	126.4		10.2
Less: imputed lease interest	(24.3)		(1.3)
Total lease liabilities	$	102.1	$	8.9

Leases

The components of lease expense were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Operating lease cost	$	8.0	$	6.9	$	22.5	$	20.3
Finance lease - amortization of right-of-use (ROU) assets	0.4		0.5		1.4		1.2
Finance lease - interest on lease liabilities	0.1		—		0.2		0.1
Short-term lease cost	1.2		1.0		3.2		2.5
Variable lease cost	2.3		2.9		7.8		8.3
Total lease cost	$	12.0	$	11.3	$	35.1	$	32.4

The following table summarizes the finance lease amounts in the condensed consolidated balance sheets:



		September 30,		December 31,
($ in millions)	Balance Sheet Classification	2026		2025

ROU assets, net	Other noncurrent assets	$	37.5	$	34.7
Lease liabilities (current)	Other current liabilities	$	1.4	$	1.5
Lease liabilities (noncurrent)	Other long-term liabilities	$	7.5	$	3.6

Supplemental cash flow information related to leases was as follows:


	Nine Months Ended September 30,
($ in millions)		2026		2025
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		$	21.3	$	19.6
Operating cash flows from finance leases		$	0.2	$	0.1
Financing cash flows from finance leases		$	1.2	$	0.8
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases		$	4.3	$	9.9
Finance leases		$	5.2	$	2.9

The following table shows the weighted average remaining lease terms and discount rates for our operating and finance leases as of the periods ended:


	September 30, 2026		December 31, 2025
Weighted average remaining lease term (in years):
Operating leases	8.2		8.3
Finance leases	3.9		4.4
Weighted average discount rate:
Operating leases	4.82	%	4.67	%
Finance leases	4.76	%	4.15	%

Maturities of the Company's lease liabilities as of September 30, 2026 were as follows:


($ in millions)
Year	Operating Leases		Finance Leases
2026 (remaining period as of September 30, 2026)	$	6.9	$	0.4
2027	23.1		1.5
2028	21.0		1.3
2029	15.5		0.8
2030	8.3		5.7
Thereafter	51.6		0.5
	126.4		10.2
Less: imputed lease interest	(24.3)		(1.3)
Total lease liabilities	$	102.1	$	8.9

Leases - Schedule of Lease Cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Leases [Abstract]
Operating lease cost	$ 8.0	$ 6.9	$ 22.5	$ 20.3
Finance lease - amortization of right-of-use (ROU) assets	0.4	0.5	1.4	1.2
Finance lease - interest on lease liabilities	0.1	0.0	0.2	0.1
Short-term lease cost	1.2	1.0	3.2	2.5
Variable lease cost	2.3	2.9	7.8	8.3
Total lease cost	$ 12.0	$ 11.3	$ 35.1	$ 32.4

Revenue

9 Months Ended

Sep. 30, 2026

Revenue from Contract with Customer [Abstract]

Revenue

Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

The following table presents the approximate percentage of our net sales by market group:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Biologics	43 %	41 %	43 %	39 %
Generics	15 %	17 %	15 %	17 %
Pharma	25 %	22 %	25 %	25 %
West Vantage	17 %	20 %	17 %	19 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by product category:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
High-Value Product ("HVP") Components	53 %	48 %	50 %	47 %
High-Value Product ("HVP") Delivery Devices	11 %	12 %	14 %	13 %
Standard Packaging	19 %	20 %	19 %	21 %
West Vantage	17 %	20 %	17 %	19 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by geographic location:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Americas	46 %	47 %	45 %	47 %
Europe, Middle East, Africa	43 %	45 %	45 %	45 %
Asia Pacific	11 %	8 %	10 %	8 %
	100 %	100 %	100 %	100 %

Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities:


	($ in millions)
Contract assets, December 31, 2025	$	11.9
Contract assets, September 30, 2026	15.1
Change in contract assets - increase (decrease)	$	3.2

Deferred income, December 31, 2025	$	(53.7)
Deferred income, September 30, 2026	(43.7)
Change in deferred income - decrease (increase)	$	10.0

Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2026, $37.4 million of revenue was recognized that was included in deferred income at the beginning of the year.

As of September 30, 2026, performance obligations expected to be satisfied beyond one year were $3.6 million. The remaining $40.1 million of performance obligations are expected to be satisfied within one year or less.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Affiliated Companies

9 Months Ended

Sep. 30, 2026

Equity Method Investments and Joint Ventures [Abstract]

Affiliated Companies


	September 30,		December 31,
($ in millions)	2026		2025
Aggregate carrying value of investments in affiliated companies:
Equity method affiliates	$	215.2	$	208.3
Non-equity method affiliates	0.6		4.0
Total investments in affiliated companies	$	215.8	$	212.3

We have elected to record non-equity method investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. During the nine months ended September 30, 2026, we recorded impairment charges of $3.5 million within other expense (income) to one of our cost-method investments, recorded above under non-equity method affiliates.

The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:


	September 30,		December 31,
($ in millions)	2026		2025
Payables due to affiliates	$	34.2	$	26.2
Receivables due from affiliates	$	3.6	$	2.0

The following table summarizes the Company's affiliate transactions:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Purchases from (and payments to) affiliates	$	38.0	$	25.2	$	106.3	$	83.1
Sales to affiliates	$	5.9	$	3.4	$	13.6	$	9.4

The majority of the purchase transactions listed above relate to the Company's distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that authorizes the Company as the exclusive distributor of Daikyo products in all countries other than Japan, subject to certain limited exceptions.

On July 14, 2026, the Company and Daikyo, in which the Company maintains a 49% ownership interest, entered into an Amended and Restated Technology Exchange and CrossLicense Agreement and two Distributorship Agreements, each effective July 14, 2026 with a term of ten years.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Statement of Comprehensive Income [Abstract]
Net income	$ 214.0	$ 140.0	$ 506.8	$ 361.6
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments, net of tax of $(0.9) and $0.7, $(0.4) and $(1.4), respectively	1.5	(12.0)	(32.1)	153.3
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.0 and $0.0, $0.0 and $(0.3), respectively	(0.1)	0.1	(0.3)	(1.0)
Net gain (loss) on equity affiliate accumulated other comprehensive income, net of tax of $0.0 and $0.0, $0.0 and $0.0, respectively	0.1	(0.1)	0.0	0.1
Net gain (loss) on derivatives, net of tax of $0.6 and $(0.5), $0.4 and $1.2, respectively	1.9	(1.6)	0.9	3.4
Other comprehensive income (loss), net of tax	3.4	(13.6)	(31.5)	155.8
Comprehensive income	$ 217.4	$ 126.4	$ 475.3	$ 517.4

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Derivative Financial Instruments - Schedule of Foreign Exchange Rate Risk (Details) - Sep. 30, 2026 - Foreign Exchange Forward - Designated as Hedging Instrument € in Millions, ¥ in Millions, $ in Millions, $ in Millions	USD ($)	SGD ($)	EUR (€)	JPY (¥)
EUR \| Purchase
Derivative [Line Items]
Derivative, notional amount \| €			€ 30.3
EUR \| Sell
Derivative [Line Items]
Derivative, notional amount	$ 35.8		0.0
JPY \| Purchase
Derivative [Line Items]
Derivative, notional amount \| ¥				¥ 4,943.4
JPY \| Sell
Derivative [Line Items]
Derivative, notional amount	19.1		11.2
SGD \| Purchase
Derivative [Line Items]
Derivative, notional amount \| $		$ 66.2
SGD \| Sell
Derivative [Line Items]
Derivative, notional amount	$ 46.1		€ 5.9

Net Income Per Share

9 Months Ended

Sep. 30, 2026

Earnings Per Share [Abstract]

Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Net income	$	214.0	$	140.0	$	506.8	$	361.6
Weighted average common shares outstanding	70.4		72.2		71.1		72.3
Dilutive effect of equity awards, based on the treasury stock method	0.4		0.4		0.4		0.4
Weighted average shares assuming dilution	70.8		72.6		71.5		72.7

During the three months ended September 30, 2026 and 2025, there were 0.1 million and 0.4 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.3 million and 0.4 million antidilutive shares outstanding during the nine months ended September 30, 2026 and 2025, respectively.

In February 2023, the Board of Directors approved a share repurchase program under which the Company was able to repurchase up to $1.0 billion in shares of common stock. This program was completed during January 2025.

In December 2024, the Board of Directors approved a share repurchase program under which the Company was able to repurchase up to 550,000 shares of common stock. This program was completed during April 2025.

In February 2026, the Company’s Board of Directors authorized a new share repurchase program for the purchase of up to $1.0 billion of the Company’s common stock in open-market transactions, block transactions, through derivative transactions, privately negotiated transactions, or otherwise, including pursuant to any trading plan entered into by the Company under Rule 10b5-1 of the Exchange Act. The number of shares to be repurchased and the timing of any repurchases will depend on factors such as the stock price, economic and market conditions, and corporate and regulatory requirements. This share repurchase program has no expiration date and it may be suspended or terminated at any time.

The following table summarizes the details of the Company's repurchases of common stock under these programs:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026		2026		2025
Shares repurchased	663,511		2,424,121		552,593
Total cost of repurchases ($ in millions)	$	231.0	$	685.3	$	134.0
Average price per repurchased share	$	348.11	$	282.68	$	242.55

Net Income Per Share (Tables)

9 Months Ended

Sep. 30, 2026

Earnings Per Share [Abstract]

Schedule of Reconciliation of Basic to Diluted Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2026		2025		2026		2025
Net income	$	214.0	$	140.0	$	506.8	$	361.6
Weighted average common shares outstanding	70.4		72.2		71.1		72.3
Dilutive effect of equity awards, based on the treasury stock method	0.4		0.4		0.4		0.4
Weighted average shares assuming dilution	70.8		72.6		71.5		72.7

Schedule of Repurchase of Common Stock

The following table summarizes the details of the Company's repurchases of common stock under these programs:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026		2026		2025
Shares repurchased	663,511		2,424,121		552,593
Total cost of repurchases ($ in millions)	$	231.0	$	685.3	$	134.0
Average price per repurchased share	$	348.11	$	282.68	$	242.55

Derivative Financial Instruments - Narrative (Details) $ in Millions, ¥ in Billions	3 Months Ended		9 Months Ended
	Sep. 30, 2026 USD ($) $ / bbl	Sep. 30, 2025 USD ($)	Sep. 30, 2026 USD ($) $ / bbl bbl	Sep. 30, 2025 USD ($)	Sep. 30, 2026 JPY (¥) $ / bbl	Jul. 31, 2024 USD ($)
Fair Value Hedging
Derivative [Line Items]
Derivative, forward point components, (loss) gain, recognized in earnings	$ 0.4	$ 0.4	$ (0.5)	$ 1.3
Foreign Exchange Forward
Derivative [Line Items]
Derivative contract term			18 months
Options Held
Derivative [Line Items]
Derivative, nonmonetary notional amount, volume \| bbl			227,960
Derivative, average price risk option strike price \| $ / bbl	83.16		83.16		83.16
USD \| Cross Currency Interest Rate Contract \| Net Investment Hedging
Derivative [Line Items]
Derivative, notional amount	$ 130.0		$ 130.0			$ 130.0
JPY \| Cross Currency Interest Rate Contract \| Net Investment Hedging
Derivative [Line Items]
Derivative, notional amount \| ¥					¥ 17.0

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2026
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2026, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Annual Report”). The results of operations for any interim period are not necessarily indicative of the results for the full year. West Vantage: Effective in the first quarter of 2026, the Company renamed its "Contract-Manufactured Products" reportable segment to "West Vantage™" to better align with its current strategic focus and offerings. This change in name does not affect the composition of the reportable segment, nor does it impact previously reported segment financial information. Sale of SmartDose® 3.5mL On-Body Delivery System: On July 1, 2026, the Company completed the sale of all manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie for $126.9 million cash, inclusive of working capital adjustments. We recognized a $55.7 million pre-tax gain on this transaction within other expense (income) in our Condensed Consolidated Statements of Income during the three and nine months ended September 30, 2026. In relation to this agreement, the carrying values of certain assets (Inventories - $20.5 million, Property, plant and equipment, net - $39.1 million, Operating lease right-of-use assets - $1.2 million, and Goodwill - $0.6 million) were classified as held for sale in our consolidated balance sheets as of December 31, 2025 and recorded in other current assets within our Proprietary Products segment.

Derivative Financial Instruments - Schedule of Foreign Exchange Contracts (Details) - Currency Forwards € in Millions, $ in Millions	Sep. 30, 2026 SGD ($)	Sep. 30, 2026 EUR (€)	Dec. 31, 2025 SGD ($)	Dec. 31, 2025 EUR (€)
SGD \| Intercompany Loans
Derivative [Line Items]
Derivative, notional amount \| $	$ 209.1		$ 421.9
EUR \| Intercompany Demand Notes
Derivative [Line Items]
Derivative, notional amount \| €		€ 23.5		€ 23.5

Inventories

9 Months Ended

Sep. 30, 2026

Inventory Disclosure [Abstract]

Inventories

Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:


($ in millions)	September 30, 2026		December 31, 2025
Raw materials	$	170.1	$	163.2
Work in process	95.4		103.2
Finished goods	199.2		177.5
	$	464.7	$	443.9

Segment Information - Schedule of Segment Financial Information Footnote (Details) $ in Millions		3 Months Ended		9 Months Ended
	Jul. 01, 2026 USD ($)	Sep. 30, 2026 USD ($) program	Sep. 30, 2025 USD ($) program	Sep. 30, 2026 USD ($) program	Sep. 30, 2025 USD ($) program
Segment Reporting [Line Items]
Number of restructuring program \| program		2	2	2	2
Pre-tax gain on the sale of assets		$ 55.7	$ 0.0	$ 55.7	$ 0.0
Other expense (income) (Note 14)		(51.2)	6.9	(34.4)	32.7
Selling, general and administrative expenses		112.9	102.7	330.0	286.6
Cost-method investment impairment charges		0.0	0.0	3.5	0.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| SmartDose® 3.5mL On-Body Delivery System And Associated Facilities
Segment Reporting [Line Items]
Pre-tax gain on the sale of assets	$ 55.7	55.7		55.7
Other expense (income) (Note 14)		1.9		0.3
Selling, general and administrative expenses		3.6		9.7
Corporate And Reconciling Items
Segment Reporting [Line Items]
Restructuring and related charges		6.3	2.5	9.3	21.9
SmartDose® 3.5mL sale		(54.0)	0.0	(45.7)	0.0
Cost-method investment impairment charges				3.5	0.0
Amortization of acquisition-related intangible assets			0.0	0.0	0.2
Corporate And Reconciling Items \| Affiliated Entity
Segment Reporting [Line Items]
Cost-method investment impairment charges				3.5
Corporate And Reconciling Items \| Income Statement Location [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense
Segment Reporting [Line Items]
Restructuring and related charges		0.5	1.6	1.6	4.4
Corporate And Reconciling Items \| Income Statement Location [Axis]: wst:OtherIncomeExpense
Segment Reporting [Line Items]
Restructuring and related charges		$ 5.8	$ 0.9	$ 7.7	$ 17.5

Derivative Financial Instruments - Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ 0.4	$ (0.4)	$ (0.5)	$ (1.3)
Cash flow hedges, amount of gain (loss) recognized in OCI	1.0	(1.7)	(1.7)	2.2
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	1.1	(0.1)	2.6	0.2
Net investment hedges, amount of gain (loss) recognized in OCI	(3.0)	2.4	(1.2)	(3.8)
Net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	0.0	0.0	0.0
Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Fair value hedges, amount of gain (loss) recognized in OCI	(0.2)	0.2	0.0	1.0
Fair value hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	0.0	0.0	0.0
Foreign currency hedge contracts \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Fair value hedges, amount of gain (loss) recognized in OCI	(0.2)	0.2	0.0	1.0
Fair value hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	0.0	0.0	0.0
Forward treasury locks
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedges, amount of gain (loss) recognized in OCI	0.0	0.0	0.0	0.0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.1	0.1	0.1	0.1
Cross-currency swap
Derivative Instruments, Gain (Loss) [Line Items]
Net investment hedges, amount of gain (loss) recognized in OCI	(3.0)	2.4	(1.2)	(3.8)
Net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	0.0	0.0	0.0
Income Statement Location [Axis]: us-gaap:CostOfGoodsAndServicesSold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instruments, net, pretax	1.1	(0.5)	2.2	(0.3)
Income Statement Location [Axis]: us-gaap:CostOfGoodsAndServicesSold \| Foreign currency hedge contracts
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedges, amount of gain (loss) recognized in OCI	0.2	(2.5)	(2.4)	4.0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	1.1	(0.5)	2.2	(0.3)
Income Statement Location [Axis]: us-gaap:InterestExpenseNonoperating
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instruments, net, pretax	0.1	0.1	0.1	0.1
Income Statement Location [Axis]: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative instruments, net, pretax	(0.1)	0.3	0.3	0.4
Income Statement Location [Axis]: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax \| Foreign currency hedge contracts
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedges, amount of gain (loss) recognized in OCI	0.8	0.8	0.7	(1.8)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	(0.1)	0.3	0.3	0.4
Income Statement Location [Axis]: wst:OtherIncomeExpense
Derivative Instruments, Gain (Loss) [Line Items]
Hedged item (intercompany loan)	(3.3)	3.9	(8.2)	7.3
Derivative designated as hedging instrument	3.3	(3.9)	8.2	(7.3)
Amount excluded from effectiveness testing	$ 0.4	$ (0.4)	$ (0.5)	$ (1.3)

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2026
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights ("SARs"), restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. In March 2025, the Board of Directors approved, and our stockholders subsequently approved in May 2025, an amendment to the 2016 Plan ("the Amended and Restated 2016 Plan"), which, among other things, added 2.0 million shares of common stock to the maximum number of shares of common stock as to which awards may be granted. Following the approval of the Amended and Restated 2016 Plan, all stock options or SARs that are not forfeited or cancelled will reduce the number of shares available for issuance under the Amended and Restated 2016 Plan by one share for each share subject to the award. Awards issued following the amendment that are payable in common stock (other than stock options or SARs) will reduce the total number of shares available for grant under the Amended and Restated 2016 Plan by an amount equal to 2.0 times the number of shares subject to the award. The reduction was previously equal to 2.5 times the number of shares subject to the award under the 2016 Plan. At September 30, 2026, there were approximately 2.7 million shares remaining in the Amended and Restated 2016 Plan for future grants. During the nine months ended September 30, 2026, the Company granted 104,187 stock options at a weighted average exercise price of $285.51 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $123.37 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.1%; expected life of 6.9 years based on prior experience; stock volatility of 35.1% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures. During the nine months ended September 30, 2026, the Company granted 81,450 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $278.08 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. During the nine months ended September 30, 2026, the Company granted 54,154 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $279.63 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. Stock-based compensation expense was $4.3 million and $21.8 million for the three and nine months ended September 30, 2026. For the three and nine months ended September 30, 2025, stock-based compensation expense was $8.4 million and $17.1 million, respectively.

Accumulated Other Comprehensive Loss

9 Months Ended

Sep. 30, 2026

Equity [Abstract]

Accumulated Other Comprehensive Loss

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2026:


($ in millions)	Derivatives		Change in equity affiliate investment AOCI		Defined benefit pension and other postretirement plans		Foreign currency translation		Total
Balance, December 31, 2025	$	(1.5)	$	3.2	$	(8.1)	$	(99.1)	$	(105.5)
Other comprehensive income (loss) before reclassifications	(1.7)		—		—		(32.1)		(33.8)
Amounts reclassified out from accumulated other comprehensive income (loss)	2.6		—		(0.3)		—		2.3
Other comprehensive income (loss), net of tax	0.9		—		(0.3)		(32.1)		(31.5)
Balance, September 30, 2026	$	(0.6)	$	3.2	$	(8.4)	$	(131.2)	$	(137.0)

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2025:


($ in millions)	Derivatives		Change in equity affiliate investment AOCI		Defined benefit pension and other postretirement plans		Foreign currency translation		Total
Balance, December 31, 2024	$	(2.5)	$	2.5	$	(9.8)	$	(248.3)	$	(258.1)
Other comprehensive income (loss) before reclassifications	3.2		0.1		(0.6)		153.3		156.0
Amounts reclassified out from accumulated other comprehensive income (loss)	0.2		—		(0.4)		—		(0.2)
Other comprehensive income (loss), net of tax	3.4		0.1		(1.0)		153.3		155.8
Balance, September 30, 2025	$	0.9	$	2.6	$	(10.8)	$	(95.0)	$	(102.3)

A summary of the reclassifications out from accumulated other comprehensive loss is presented in the following table:


($ in millions)	Three Months Ended September 30,				Nine Months Ended September 30,
Detail of components	2026		2025		2026		2025		Location on Statement of Income
(Losses) gains on derivatives:
Foreign currency contracts	$	—	$	(0.4)	$	(0.4)	$	(0.5)	Net sales
Foreign currency contracts	(1.3)		0.5		(2.9)		0.2		Cost of goods and services sold

Forward treasury locks	(0.1)		—		(0.1)		(0.1)		Interest expense
Total before tax	(1.4)		0.1		(3.4)		(0.4)
Tax benefit	0.3		—		0.8		0.2
Net of tax	$	(1.1)	$	0.1	$	(2.6)	$	(0.2)
Amortization of defined benefit pension and other postretirement plans:


Actuarial gains	$	0.1	$	0.2	$	0.2	$	0.5	(a)

Other	0.1		—		0.2		—
Total before tax	0.2		0.2		0.4		0.5
Tax expense	(0.1)		—		(0.1)		(0.1)
Net of tax	$	0.1	$	0.2	$	0.3	$	0.4
Total reclassifications for the period, net of tax	$	(1.0)	$	0.3	$	(2.3)	$	0.2

(a) This component is included in the computation of net periodic benefit cost.

Revenue - Narrative (Details) $ in Millions	9 Months Ended
Revenue - Narrative (Details) $ in Millions	Sep. 30, 2026 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue recognized that was included in the deferred income balance	$ 37.4
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 40.1
Revenue, remaining performance obligation, period (in years)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 3.6
Revenue, remaining performance obligation, period (in years)